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Introduction: Tuberculous (TB) meningitis is the most lethal and disabling form of TB. 
A disproportionate burden of TB meningitis is in resource-limited settings. There is 
considerable variation in mortality and neurological sequelae reported for TB meningitis 
across available studies, the reasons for which remain unclear. Delayed diagnosis and 
treatment, which is a risk factor for poor outcomes, is caused in part by lack of 
availability of diagnostic tests that are both rapid and accurate. Several attempts have 
been made to develop clinical prediction tools to fill this gap, but none have performed 
sufficiently well to be broadly implemented. 
Purpose: We aimed to (1) ascertain heterogeneity in TB meningitis outcomes; (2) 
develop and validate a clinical prediction tool for diagnosing TB meningitis; and (3) 
externally validate this clinical prediction tool to determine the overall accuracy of 
classification. 
Methods: We conducted two systematic reviews: one to identify studies reporting TB 
meningitis mortality and neurological sequelae and another to identify studies that 
undertook diagnostic testing for TB meningitis to obtain individual participant data (IPD) 
from. From the first systematic review, we conducted a meta-analysis of TB meningitis 
mortality and neurological sequelae from studies that met the inclusion criteria. We 
assessed heterogeneity in mortality by conducting stratified analyses by time of reported 
outcome, HIV status, geographic location, and year published. From the second 
systematic review, we contacted the authors and attained permission to use IPD from 
studies that met the inclusion criteria. We harmonized the data and imputed for missing 
values when possible. Three multivariate prediction model (MPM) development 
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strategies were employed to develop the clinical prediction tool for TB meningitis cases. 
First, an IPD meta-analysis using a logistic regression MPM with stratified intercepts for 
each country was fitted with key predictors. Then, we developed classification and 
regression tree (CART) and random forest MPMs with machine learning methods. All 
three MPMs were internally validated and assessed for performance using all available 
data in a k-fold internal-external cross-validation (IECV) approach. In our final analysis, 
we externally validated all three MPMs in a dataset that was not used in the development 
stage.  
Results: In our first systematic review and meta-analysis, pooled six-month mortality 
was 24% and showed significant heterogeneity (I2 >95%; p<0.01). Physical disability was 
reported in 32% (95%CI; 22-43%) of TB meningitis survivors. The heterogeneity in 
mortality was partly explained by HIV status and geographic location. Mortality ranged 
from 2% to 67% in Asian studies and from 23% to 80% in sub-Saharan African studies. 
Mortality was significantly worse in HIV-positive persons and in persons from studies 
conducted in sub-Saharan Africa. In our second systematic review, we identified and 
obtained IPD from 15 studies with a total of 3,671 individual participants. All three 
MPMs indicated cerebrospinal fluid (CSF) white blood cell (WBC) count, WBC 
differential, CSF glucose, CSF cryptococcal antigen, and blood glucose as significant 
predictors of TB meningitis. IECV revealed significant heterogeneity in performance 
between IPD studies, which varied based on the prevalence of HIV in the IPD study. 
Overall, the machine learning MPMs were not superior in performance to the logistic 
MPM; however, random forest performed slightly better than the logistic MPM. In 
external validation, the logistic MPM outperformed both CART and random forest.  
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Discussion: Results from these studies indicate the significant contribution HIV co-
infection has on outcomes and clinical prediction tool performance for TB meningitis. 
MPMs based on clinical and lab values more readily accessible in resource-limited 
settings yield well-performing clinical prediction tools. The logistic MPM had the best 
performance and external validity in an HIV-prevalent setting for TB meningitis.    
Conclusion: Heterogeneity in TB meningitis outcomes and diagnostic performance 
persist. HIV-status and geographic location are major contributors to variation in TB 
meningitis outcomes. We were successful in developing a model that can better account 
for this heterogeneity. The logistic MPM poses a generalizable clinical prediction tool 
with the potential to reduce the delay in diagnosis, and subsequent poor outcomes, in TB 
meningitis.      
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CHAPTER 1. OVERVIEW OF TUBERCULOUS MENINGITIS DIAGNOSTICS 
 
This dissertation aims to improve the diagnostic strategy for tuberculous (TB) 
meningitis. In Manuscript 1, we aim to ascertain heterogeneity in TB meningitis mortality 
and neurological sequelae via systematic review and meta-analysis. In Manuscript 2, we 
aim to build a clinical prediction tool using machine learning methods. Our goal is to 
address the underlying heterogeneity observed in Manuscript 1 as well as account for 
case-mix variation so that the clinical prediction tool is built to perform well in any 
population or setting. For Manuscript 3, we aim to externally validate the clinical 
prediction tool developed in Manuscript 2 in a population in Uganda. This chapter 
describes the epidemiology of TB meningitis, the context of TB meningitis diagnostic 
challenges, clinical prediction tools, and machine learning methods. 
 
Epidemiology of Tuberculous Meningitis 
Tuberculosis (TB) is a disease caused by the infection of the bacillus 
Mycobacterium tuberculosis.1 M. tuberculosis is spread by small airborne droplets 
generated when a person with pulmonary TB coughs, sneezes, or otherwise expels 
bacteria into the air.1 These droplets can remain airborne for up to a few hours after 
expectoration. Introduction of M. tuberculosis into the lungs leads to infection of the 
respiratory system (pulmonary TB) but the infection can also spread to other sites in the 
body (extrapulmonary TB) including the brain and central nervous system.1 TB 
meningitis is caused when M. tuberculosis enters the cerebrospinal fluid (CSF), leading 
to inflammation of the meninges, causing meningitis.2  
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Globally, 10 million cases of TB were reported in 2019, and TB is currently the 
leading cause of mortality from a single infectious agent worldwide.1 According to the 
World Health Organization (WHO), about a quarter of the world’s population is infected 
with M. tuberculosis.1 TB is a disease of poverty, economic distress, vulnerability, and 
marginalization. Consequently, 90% of cases are derived from 30 high-TB burden 
countries.1 TB meningitis accounts for 1-5% of global TB cases, and at least 100,000 
cases are estimated annually.3 The proportion of TB meningitis in people living with TB 
varies considerably by TB prevalence, age, and HIV. HIV co-infection is the most 
significant risk factor for TB meningitis in adults.4 However, our understanding of the 
global burden of TB meningitis is poor. Many cases of TB meningitis remain 
undiagnosed due to inadequate diagnostic test performance and lack of available testing 
availability, so population-based estimates of TB meningitis incidence are often not 
reported and challenging to determine.3,4 
Although TB meningitis disproportionately impacts resource-limited settings, TB 
meningitis accounts for the highest proportion of TB deaths in both resource-rich and -
limited settings.3 TB meningitis is the most devastating form of TB, with an estimated 
mortality of 16% (95% Confidence Interval (CI): 10-24%) among HIV-negative patients, 
and 57% (95% CI; 48-67%) among HIV-positive patients.3,5  In the absence of treatment, 
TB meningitis is uniformly fatal.4  Up to 50% of survivors suffer from long-term 
neurologic sequelae such as blindness, stroke, and seizures.4 Delays in diagnosis and 
treatment initiation are major contributing factors to the high morbidity and mortality in 




Challenges in Tuberculous Meningitis Diagnostics 
Identifying the etiology of meningitis is challenging since many of the 
discriminating clinical symptoms are often nonspecific and subacute.2,6 Adults with TB 
meningitis commonly present with stiff neck, headache, fever and vomiting, which are 
symptoms commonly seen with other forms of bacterial meningitis.6 However, patients 
with TB meningitis typically report longer symptom duration—up to 1 month–with 
symptoms that are consistent with pulmonary TB infection such as cough, night sweats, 
and weight loss.6,7 TB meningitis presentation is also characterized by a higher 
likelihood of neurologic symptoms such as altered mental status,  personality changes, 
cranial nerve neuropathy (typically cranial nerve IV), and coma.7 Routine evaluation of 
cerebrospinal fluid (CSF) may help elucidate meningitis etiology. TB meningitis is 
generally thought of as causing an increase in lymphocytic white blood cell (WBC) 
count with elevated protein and low glucose in CSF.8 However, there is no typical 
pattern of CSF values that can reliably distinguish TB meningitis from other meningitis 
etiologies, particularly in the presence of HIV co-infection.8  
Diagnostic tests aimed at identifying M. tuberculosis in CSF are lengthy, have 
poor diagnostic performance, and/or unavailable in resource-limited settings. While 
recently introduced nucleic acid amplification tests (NAATs) that test for the DNA of 
TB have the potential to improve timeliness of diagnosis, the moderate sensitivity (50-
70%) means that negative tests cannot fully exclude disease.9 This is largely 
attributable to the pauci-bacillary nature of TB meningitis. Due to significant 
inflammation in the brain and subsequent poor CSF circulation, it is possible to have 
TB meningitis with very low or no M. tuberculosis in the CSF.8 Diagnostic approaches 
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that rely on microbiologic confirmation will inevitably miss cases of TB meningitis, 
further delaying treatment. Delayed treatment is the main risk factor for death for TB 
meningitis.3 Thus, diagnostic approaches for TB meningitis must include a combination 
of microbiologic and clinical assessments that can better encompass pauci-bacillary and 
bacillary case types of TB meningitis. 
A major stumbling block in TB 
meningitis research had been the absence 
of a single reference standard test or 
criteria for the diagnosis of TB meningitis. 
In 2010, a committee of 41 international 
TBM experts developed a standardized 
criteria, known as a case definition, for the 
diagnosis of TB meningitis to use in future 
clinical research called the Uniform TB 
Meningitis Case Definition (UTBMCD) 
(Table 1.1).10 The UTBMCD has helped 
to standardize research, but it cannot be 
used as an immediate clinical diagnostic 
tool because it depends on delayed results, 
such as mycobacterial culture, which can 
take up to 8 weeks for growth to occur.3 
The UTBMCD also includes brain 
imaging to define the diagnosis of TB 
Table 1.1. Uniform TBM Case Definition  
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meningitis, which is not available in many resource-limited settings.3 Having a rapid 
diagnostic test ensures that the patient can begin treatment at the earliest possible time. 
Due to the brain damage that TB meningitis causes and high risk of long-term disability 
and death, TB meningitis is a medical emergency.3 Availability of a diagnostic method 
that facilitates early diagnosis and prompt treatment could save lives and reduce 
neurologic disability in survivors. Improving the strategies for rapid and efficient TB 
meningitis diagnosis is an urgent need.3 
 
Multivariate Prediction Models & Clinical Prediction Tools 
Another approach to improving rapid TB meningitis diagnosis, particularly in 
resource-limited settings, is to develop a clinical prediction tool based on a multivariate 
prediction model (MPM). A MPM is a mathematical algorithm based on several inputs, 
or variables, formulated with the aid of statistical modeling that predicts the probability 
of having a disease. The statistical modeling determines which criteria are most 
predictive of the presence of a disease, typically patient characteristics (such as age or 
sex) or biological markers found in human specimens that can be measured in a clinical 
laboratory.  
The advantage of a MPM is that the prediction of TB meningitis is based on 
patient characteristics and biological markers that differentiate TB meningitis from 
other types of meningitis. This is a novel approach to the diagnosis of TB meningitis 
that overcomes the challenge of prior diagnostic methods, such as the UTBMCD and 
NAATs, which focus on identifying the pathogen.  
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At least ten clinical prediction tools have been published for the diagnosis of TB 
meningitis (see Table 1.2).  
Table 1.2. Published Clinical Prediction Tools for TB Meningitis  
Citation Population Case comparison Predictors of TB Meningitis 
Kumar 11 Children from 
India  
TBM versus other 
meningitis  
Symptoms ≥7 days 
Optic atrophy 
Focal neurological deficit  
Extrapyramidal movements  
CSF leukocytes <50% neutrophils  
Thwaites 12 Adults from 
Vietnam  
TBM versus 
bacterial meningitis  
Age <36 years 
Blood leukocytes <15 × 109/l  
Symptoms ≥6 days 
CSF leukocytes <750/mm3  
CSF neutrophils <90%  




bacterial meningitis  
Symptoms >5 days 
CSF leukocytes <1000/mm3  
Clear CSF  
CSF lymphocytes >30%  
CSF protein >100 mg/L 






Low CSF opening pressure  
Neck stiffness  
Raised CSF leukocytes  
Low Glasgow Coma Scale score 
High fever  
Patel15 Adults from 
South Africa 
(84% HIV+)  
TBM versus other 
meningitis  
CSF:blood glucose ratio ≤0.2  
CSF lymphocytes >200/mm3  
CD4+ cell count <200 × 106/L  
Negative cryptococcal antigen test  
Hristea16 Adults from 
Turkey  
TBM versus viral 
meningitis  
Symptoms ≥5 days  
MRC grade II or III  
CSF:blood glucose ratio <0.5  
CSF protein >100 mg/dL 
Vibha17  Adults from 
India  
TBM versus 
bacterial meningitis  
Living in a rural area  
Symptoms ≥6 days  
Cranial nerve palsy  
Hemiplegia  
Clear CSF  
CSF neutrophils <75% 
Dendane18 Adults from 
Morocco  
TBM versus 
bacterial meningitis  
Female sex  
Symptoms ≥0 days  
Focal neurological deficits  
Blood leukocytes <15 × 109/L  
Plasma sodium <130 mmol/L 
CSF leukocytes <400/mm3  






Female sex  
Reduced consciousness  
No visual or hearing loss  
Evidence of extraneural tuberculosis  
CSF leukocytes ≥68/mm3  
CSF protein >0.91 mg/dL 
Qamar 20 Children from 
Pakistan  
TBM versus 
bacterial meningitis  
Hydrocephalus on brain CT  
CSF leukocytes <800/mm3  
CSF protein:glucose ratio ≥2  
CSF, cerebrospinal fluid; MRC, Medical Research Council; TBM, tuberculous meningitis. 
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A major limitation of prior clinical prediction tools is that their performance is variable 
in different populations and settings. Only a few of these scoring systems have been 
externally validated.3 External validation refers to the ability for a statistical model to 
perform well in a dataset or population separate from the dataset or population in which 
it was developed. Thus, if a tool or model is ‘externally validated’, then it performs 
well in any setting, population, or dataset. The primary contributing factor of varied 
model performance across different settings and populations is case-mix variation, 
which refers to the distribution of important population characteristics such as HIV 
status, age, and the population prevalence of TB. Case-mix variation across different 
settings can lead to genuine differences in the performance of a prediction model, even 
when the criteria truly predict the disease.25 Prior clinical prediction tools were 
developed from a single site, including the tool developed by Thwaites et al.,12 and 
therefore have not adequately accounted for case-mix variation. This impacts accuracy 
and clinical utility when applied to other populations and settings. 
 
Conceptual Model: Diagnosis to Death 
 We have designed a conceptual model to illustrate the objectives of this 
dissertation, challenges in TB meningitis research, and pathways that we will explore in 
the three manuscripts (Figure 1.1). This conceptual model is based on the several key 
gaps in TB meningitis knowledge and research highlighted by experts in the TB 
Meningitis International Research Consortium.2,3 The conceptual model depicts the 
timeline from TB meningitis infection to death. The challenges highlighted along the 
timeline are limited to the scope of this dissertation’s objectives and are not exhaustive. 
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Manuscript 1, indicated by the blue arrows, examines the heterogeneity in outcomes of 
TB meningitis that inform important factors of case-mix variation, ultimately 
highlighting high-risk groups for infection, missed diagnosis, and death. Manuscript 2 
aims to reduce the time between TB meningitis infection and diagnosis by using MPMs 
developed from a diverse dataset to develop a clinical prediction tool to improve 
diagnostics. In Manuscript 3, we will externally validate the clinical prediction tool 
developed in Manuscript 2 and ascertain diagnostic performance.  


























 In 2018, ten million cases of tuberculosis (TB) were reported globally;26 and TB 
meningitis accounts for 1-5% of these cases.27 TB meningitis is the most severe form of 
tuberculosis and is responsible for a considerable burden of neurological sequelae and 
mortality;  a systematic review of treatment outcomes in 1,636 children with TB 
meningitis estimated 19.3% mortality.28 There is considerable variation in the reported 
outcomes for adult TB meningitis across available studies, the reasons for which remain 
unclear. Two recent systematic reviews of adult TB meningitis outcomes reported 
substantial heterogeneity in mortality, with pooled estimates of 22.8% and 24.7%.29,30 
However, neither review attempted to explain the variation in treatment outcomes by 
stratifying studies by HIV status and geographical location. In addition, Wen and 
colleagues excluded all investigational treatment studies effectively excluding major 
treatment randomized controlled trials (RCTs) investigating regimens that have now 
become the standard of care (e.g., adjunctive steroids and delayed antiretroviral therapy 
(ART) for those with HIV-associated TB meningitis). Furthermore, there is a paucity of 
data in recent meta-analyses on drug resistance rates, treatment regimens, and steroid use. 
HIV co-infection has been shown to be a risk factor for death (Hazard Ratio 2.5; 95% CI 
1.9-3.4) in Vietnamese adults with TB meningitis,31 but this remains to be explored 
systematically in other regions.32-34 Similarly, neurological disability in adult TB 
meningitis survivors has not been studied in detail in meta-analyses. In two recent 
systematic reviews, prevalence of disability in adult TB meningitis survivors varied 
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between 29% and 50%.29,30 However neither review provided data on the nature and 
severity of neurological sequelae in TB meningitis survivors.  
We performed a systematic review and meta-analysis to characterize treatment 
outcomes, namely all-cause mortality and neurological sequelae, for adult TB meningitis 
across a range of epidemiological settings. We endeavored to perform a definitive review 
by including the best quality data available and performing a robust quality assessment of 
the studies included.  
Methods 
Literature search strategy 
This review followed the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement for the reporting of systematic reviews and meta-
analyses.35 A systematic electronic search was conducted using MEDLINE and 
EMBASE with the aim of identifying all studies reporting treatment outcomes in adult 
TB meningitis from 1988 to present. This time period corresponds to the WHO 
recommendation of standard quadruple therapy for the treatment of TB.26 Controlled and 
natural language terms identified key search concepts such as: “tuberculosis”, 
“meningitis”, “mortality”, “complications” and “outcome.” Full search strategies are 
presented in Appendix A. Searches were conducted on 9 July 2018.   
Study selection 
  A two-stage sifting process was employed: (1) at title and abstract; and (2) at full 
text level according to eligibility criteria as detailed below. Sifting was performed in 
duplicate independently by two reviewers and any unresolved disagreements were 
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resolved by a third, independent reviewer. Reference and citation checking were 
conducted for included articles.  
Studies were eligible for inclusion if they (i) included adults (aged ≥ 15 years) 
with confirmed or suspected TB-meningitis; (ii) utilized diagnostic criterion to 
systematically evaluate patients for TB meningitis; (iii) reported on at least one of the 
following outcome measures: neurological sequelae, in-hospital mortality, mortality at 
the end of follow-up (v) employing any of the following study designs: consecutive case 
series, case control study, cohort study, randomized controlled study, systematic review, 
or meta-analysis. 
The following exclusion criteria were applied: (i) studies with fewer than 10 
participants; (ii) studies limited to specific complications or comorbidities (e.g. 
hydrocephalus, tuberculoma, or surgical intervention); (iii) studies not providing at least a 
backbone of standard fixed dose combination anti- TB therapy; (iv) studies not specifying 
treatment given; (v) studies published before 1988; (vi) studies not written in English; 
(vii) any systematic review superseded by an updated systematic review; (viii) narrative 
reviews not adding new data or new analysis of data to existing knowledge.  
Data extraction and data synthesis  
Two authors independently extracted data on study characteristics, recruitment 
populations, and treatment outcomes from eligible studies using a standardized, piloted 
electronic data capture database (REDCap, Vanderbilt University, USA). We captured 
data on geographical region, number of HIV-positive participants, British Medical 
Research Council (MRC) TB meningitis grade at presentation, treatment regimens 
utilized, use of corticosteroids, and outcomes reported at specified time points for each 
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study. Any unresolved disagreements in extraction were resolved by a third, independent 
reviewer.  
We used each study’s definition of neurological sequelae as reported in the study. 
For articles that utilized the modified Rankin Scale or the Barthel index, “disability” was 
defined as ‘any disability that impeded the patient’s ability to carry out tasks they once 
performed’. This is was represented as a score of >2 on the modified Rankin Scale or <80 
on the Barthel Index.  
For systematic reviews, individual study level data were not extracted or 
analyzed, only the summary estimates were recorded for comparison, and citation 
checking was performed to ensure all relevant source manuscripts had been identified.   
Data analysis  
We used the proportion of all-cause deaths and neurological sequelae within each 
study to define outcomes of TB meningitis for the meta-analyses. As such, all meta-
analyses used random effects models and employed the DerSimonian and Laird method 
on Freeman-Tukey transformed proportions, which is the established approach for this 
type of analysis.36-38 We graphically displayed data in forest plots, which display point 
estimates of TB meningitis outcomes in each study, with 95% confidence intervals. We 
generated pooled effect estimates by inverse-variance weighting each individual point 
estimate such that the estimates with lower variances contributed more to the pooled 
estimate.38 The overall pooled estimate for mortality was stratified by follow-up outcome 
reporting time. Inter-study and sub-group heterogeneity were assessed with the I2 
statistic. All analyses were conducted in Stata version 15.1 (StataCorp, College Station, 
TX, USA) with the “metaprop” command.39 
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Quality assessment  
The 39 articles included in the meta-analysis were assessed for study quality using 
the Downs and Black tool, a 27-item quality assessment checklist.40 Each study was 
scored on a 32-point scale for items that examined quality of reporting, external validity, 
internal validity (bias and confounding), and study power. Study power was estimated 
according to sample size methodology. Studies were scored as follows; 0 if no sample 
size calculation was made or reported in the manuscript (given for observational studies); 
3 if a power calculation was done but there were insufficient numbers of patients 
recruited; 5 if the power calculation was done and sufficiently powered. Systematic 
reviews meeting the inclusion criteria were not assessed for risk of bias. As treatment 
outcomes were of interest in these analyses and not treatment or intervention efficacy, we 
included all studies regardless of quality assessment score.  
Results 
Search results, studies, and participants included  
Our searches yielded 2,562 reports, after removal of duplicates (n=365), 2,197 
studies underwent title and abstract screening, and 264 full texts were reviewed (Figure 
2.1). 39 studies met our eligibility criteria for inclusion and analysis (Table 2.1). These 
39 studies were published between 1995 and 2018 of which: 10 (26%) were case series, 
21 (54%) were cohort studies, and eight (21%) were randomized controlled trials. Studies 
arose from 18 countries including a range of epidemiological settings; 24 (62%) were 









Records identified through 
database searching 
(n = 2562) 
Additional records identified 
through other sources 
(n = 3) 
Records after duplicates removed 
(n = 2197) 
Records screened 
(n = 2197) 
Records excluded 
(n = 1934) 
Full-text articles assessed 
for eligibility 
(n = 264) 
Full-text articles excluded (n = 225) 
Non-tuberculous meningitis (n=13) 
No systematic diagnostic criteria for diagnosing 
tuberculous meningitis (n=25) 
Did not report at least one outcome of interest (n=9) 
Ineligible study type or study type not specified (n=10) 
Fewer than 10 study participants (n=3) 
Non-English articles (n=27) 
Study conducted before 1988 (n=8) 
Study sample limited to patients with specific 
complications or comorbidities (n=5) 
Full text unable to be located (n=27) 
No disaggregated tuberculous meningitis data (n=6) 
No disaggregated adult data (n=58) 
No specified treatment drugs, doses, and duration 
(n=30) 
Narrative reviews or new analysis of existing data (n=2) 
Any systematic review superseded by an updated 




Studies included in 
qualitative synthesis 
(n = 42) 
Studies included in 
quantitative synthesis 
(meta-analysis) 




















Outcome(s) and Time 
point reported 
AFRICA 





a b  
54 
(100%) 
1 (2%) 53 (98%) 2RHZE/6-8RH 
All received steroids: 
unspecified drug(s), dose, & 
duration 
In-hospital mortality 
Marais 42 2011 Cohort South Africa 120 
2  
a b c d e f    
106 
(88%) 
47 (39%) 73 (61%) RHZE Not specified 
In-hospital and 6-
month mortality 





a b e f    
15 
(68%) 
0 (0%) 22 (100%) RHZE  Not given 
Mortality at the end of 
follow up 
Cresswell 44 2018 Cohort Uganda 195 
2  
a b c d 
106 
(54%) 















+ S if prior TB (n=2) 




2011 Cohort Mexico 64 
2  
a c f 
14 
(22%) 
44 (69%) 20 (31%) 
2RHZE/RH - mean 
time of therapy was 
11.9 ± 7 months 
57 (78%) received steroids, 




at 5 months 
Alarcon 47 2013 Cohort Ecuador 310 
2  




140 (45%) 170 (55%) 
2RHZ + E or S or 
quinolone / 10RH  
(quinolone given to 
some) 
Steroids given to patients 
with severe disease, 




at 12 months 
ASIA 
Torok 48 2008 Cohort Vietnam 58 
2  
b d e f 
58 
(100%) 
54 (93%) 4 (7%) 
3RHZE + S if prior 
TB/6RH 
 
D (0.3-0.4mg/kg) tapered 
over 6-8 weeks 
Mortality at 9 months 
Torok 49 2011 RCT Vietnam 253 
2  
a b d e f 
253 
(100%) 
158 (62%) 95 (38%) 
3RHZE + S if prior 
TB/6RH  
D (0.3-0.4mg/kg) tapered 
over 6-8 weeks  
Mortality and 
neurological outcomes 
at 9 and 12 months 




214 (26%)  
174 (21%) 
2RHZE/6RH  
+ S if prior TB 
+ L in one trial arm 
D (0.3-0.4mg/kg) for 6-8 
weeks 
Mortality at 9 months 
 





















Outcome(s) and Time 
point reported 
Thwaites 50 2002 Cohort Vietnam 56 
2  
a b d  
11 
(20%) 
56 (100%) 0 (0%) 
3RHZE/6RHZ if HIV+ 
3RHZS/6RHZ if HIV- 
Not given Mortality at 3 months 
Thwaites 51 2004 RCT Vietnam 545 
2  







3RHZE/6RHZ if HIV+ 
or prior history of TB  
D (0.3-0.4mg/kg) tapered 
over 4 weeks, then oral 
treatment (4mg/day) tapered 
for 4 weeks  
Mortality and 
neurological outcomes 




2017 Cohort Indonesia 608 
2  







(n=47: high dose R) 
(n=25: M instead of E) 
91% received steroids 
Drug, dose, and duration not 
specified 
Mortality at 12 months 
Singh 52 2016 Cohort India 141 1 
13 
(9%) 
54 (38%) 87 (62%) 2RHZS/7HE 
D (0.3-0.4mg/kg) tapered 
over 4 weeks, then oral 
treatment (4mg/day) tapered 
for 4 weeks 
Neurological outcomes 
at 9 months 
Tai 53 2016 Cohort Malaysia 36 1 3 (8%) 23 (64%) 13 (36%) 2RHZE/10RH  Not specified  
Neurological outcomes 
at 3 months 
Chen 54 2014 Cohort Taiwan 38 
2  







D (12-16mg)  
P (60-80mg) 
tapered 6-8 weeks 
Mortality and 
neurological outcomes 
at 18 months 
Kalita 55+ 2014 RCT India 60 
2  
a b c d e f 
3 (5%) 24 (40%) 36 (60%) RHZE 
P (0.5 mg/kg/day) for 1 
month, tapered over 4 weeks 
Mortality and 
neurological outcomes 
at 6 months 











RHZE +/- S  
Either D 12-16mg/day 


















+ 8% (n=34) received 
S 




at 2 months 
Chotmongkol 
58 
1996 RCT Thailand 59 2 a 0 (0%) 6 (10%) 53 (90%) 2RHZS/4RH 
29 (52%) P 60mg tapered 
over 5 weeks 
Mortality and 
neurological outcomes 
























Outcome(s) and Time 
point reported 
Lu 59 2001 Cohort China 36 
2  
a c d e f   
0 
(0%) 
23 (64%) 13 (36%) 
RHZE +/- C 
and/or S for drug 
toxicity  
Unspecified steroid given to patients 
with clinical deterioration 
Mortality and 
neurological outcomes 
at 3 and 6 months 
Wang 60 2002 Cohort China 41 
2  
a d f g 
0 
(0%) 
22 (54%) 19 (46%) RHZE  
Unspecified steroid given to 9 
patients 








a b d  
0 
(0%) 
2 (4%) 42 (93%) 2RHZS/4RH Not given  Mortality at 6 months 
Thwaites 62 2003 Cohort Vietnam 21 
2  
a b d e f g 
0 
(0%) 
15 (71%) 6 (29%) 3RHZS/6RHZ  Not given 
Mortality and 
neurological outcomes 
at 9 months 
Malhotra 63 2009 RCT India 91 
2  
a b e f  
0 
(0%) 
18 (20%) 73 (80%) 2RHZE or S/7RH  
D (0.3-0.4mg/kg) tapered over 4 
weeks, then oral treatment 
(4mg/day) tapered for 4 weeks OR 
MP 5 days OD of either 1 g 




at 6 and 18 months 









46 (43%) 62 (57%) 
6RHZ,+  
S, C, or L in case 
of toxicity or side 
effects 
P (minimum 20mg) for >7 days 
given for 1 to >4 weeks in n=106 
Mortality at 9 months 





a e f g 
0 
(0%) 
4 (10%) 38 (90%) RHZE  
Six weeks of steroids, unspecified 
drug(s) & dose 
Mortality and 
neurological outcomes 
at 6 months 
Sun 66 2014 Cohort China 33 
2  
a d e f h 
0 
(0%) 
7 (21%) 26 (79%) 
RHZE +/- PAS + 
L if in trial arm 2 
D 1.5 - 15 mg/d for 1.5-6 weeks 
In-hospital 
neurological outcomes 









34 (34%) 0 (0%) 9RHZE/9RH 




at 6 months 









35 (44%) 45 (56%) 
RHZE  
+ 4% received S, 
M, and A 
D (med 21mg/day) 
P (med 40mg/day) over 3-9 weeks 
Mortality and 
neurological outcomes 
at 12 months 
Zhang 69 2016 Cohort China 401 1 
0 
(0%) 



























RCT  India 57 
2  
a b d e f h  
0 
(0%) 
18 (32%) 39 (68% 
6RHZE   
+ L in trial arm/12RH 
for following year  
P (0.5 mg/kg/day) for 1 
month tapered over 1 month  
Mortality and 
neurological outcomes 

















unspecified dose & duration 
Mortality and 
neurological outcomes 




RCT Vietnam 120 1 
0 
(0%) 
92 (77%) 26 (22%) 3RHZES/6RH  
D (0.3-0.4mg/kg) tapered 
over 4 weeks, then oral 
treatment (4mg/day) tapered 
for 4 weeks 
Mortality and 
neurological outcomes 





Cohort Turkey 42 
2  




10 (24%) 32 (76%) 3-6RHZE 
D (8mg) for 4-6 weeks 
given to patients who were 
stage II or III 




Cohort Turkey 72 
2  
a b d f  
0 
(0%) 
 72 (100%) 
 51%: 2RHZS/6RH  
49%: various 
combinations 12-16 
months R, H, Z, E, S 
P or D 4-6 weeks if MRC 
stage 3 diseases / signs of 
raised ICP  




Cohort Turkey 61 
2  
b d e f g h 
0 
(0%) 
19 (31%) 42 (69%) 
1RHZES/2-3RHZE/4-
9RHZ (if no 
tuberculoma 
present)/10-12RH 
P (1mg/kg/day) for 1 month, 
tapered for 4 months 




Cohort Turkey 121 
2  




52 (43%) 69 (57%) 2RHZ + E or S/7-10RH 
2D (16 mg/day) for those 
with 
neurological deficits 














All received: unspecified 




1 Diagnostic Criteria Legend; 
1= Uniform case definition 
2= Other criteria used to diagnose and categorize patients including: a=suggestive CSF picture, b=microscopy, c=Xpert / PCR, d=culture, f=evidence of extra-neural, TB, g=response to treatment, h=other (history of 
TB or contact with a TB-infected individual, positive mantoux reaction, IGM AB in the CSF, biopsy, etc.) 
2 Some participants were considered 'suspected' as well as 'confirmed' TBM 
3 TB treatment (given to all unless specified otherwise): Number of months placed in front of regimen code: R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol, S=streptomycin, L=levofloxacin, 
M=moxifloxacin, C=ciprofloxacin, A=amikacin, PAS=paraaminosalacylic acid, P=prednisolone, D=dexamethasone, MP=methylprenisolone. Where no duration of antituberculosis therapy or steroids is stated it means 
it was not clearly specified in the paper.  
* van Laarhoven et al. includes some data from 3 clinical trials in Indonesia (Ruslami R, Lancet Infect Dis, 2013, Yunivita V, Int J Intimicrob, 2016. Dian S, Antimicrob Agents Chemother. 2018). The primary studies 
were excluded from the review to avoid duplication of data.  
+ Only included participants that were treated with RHZE 




A total of 26 (67%) studies were conducted in Asia, and five (13%), five (13%), 
and two (5%) in Europe, Africa, and the Americas, respectively (Figure 2.2). Study 
quality scores ranged from eight to 32, with a score of 32 indicating the highest quality. 
Median quality score for included articles was 18 (IQR; 15-20). Our meta-analysis 
includes reported treatment outcomes for 5,752 adults with TB meningitis. Participant 
age ranged from 15 to 88 years. Seven studies included 1,078 HIV-positive patients: 302 
(28%) from Africa, and 776 (72%) from Asia. MRC TB meningitis grade was reported in 
29 studies, in which 28% (1354/4761) of participants presented with MRC grade I 
disease, 48% (2302/4761) with grade II, and 20% (967/4761) with grade III. A total of 37 
studies (n=5,623 participants) reported the classification or uniform case definition of 
enrolled participants. Of those, 40% (2,243/5,623) were microbiologically-confirmed TB 
meningitis, 49% (2,741/5,623) were suspected TB meningitis, the latter of which 
included 21% (1,013/5,623) with probable TB meningitis and 12% (663/5,623) with 
possible TB meningitis according to the uniform case definition.10  
Figure 2.2. Tuberculous Meningitis Mortality by Country 
 
TuberculosMeningitis Mortality by Country 








The most common treatment regimen was standard four-drug therapy of 
rifampicin, isoniazid, pyrazinamide, and ethambutol (RHZE) with no additional anti-TB 
drugs (n=17 studies). Seven studies used streptomycin in addition or in replacement for 
ethambutol (Table 2.1). Median treatment duration was nine months (IQR; 9-12 months). 
Corticosteroids were given to all patients in 19 studies, and to some participants in 10 
studies (Table 2.1). Treatment outcomes by corticosteroid use was examined in a meta-
analysis with included studies, but this was not the aim nor design of our meta-analysis 
and a significant amount of heterogeneity in mortality between studies was unexplained 
(Appendix B). A Cochrane meta-analysis on corticosteroid use in TB meningitis was 
published in 2016.78  
Mortality assessment and outcomes  
A wide range of mortality endpoints were reported: 15% (6/39) studies reported 
one-month mortality, 5% (2/39) studies reported two-month mortality, 8% (3/39) studies 
reported three-month mortality, 18% (7/39) studies reported six-month mortality, 13% 
(5/39) studies reported 12-month mortality, and 2% (1/39) reported five-year mortality. 
Other reported outcomes included in-hospital mortality (n=6 studies) and median-time to 
death (n=4 studies). In the six studies which reported on ‘in-hospital mortality’, only one 
study reported on the length of hospitalization which ranged from 4-10 days until death 
or discharge. Five studies did not define the ‘in-hospital mortality’ in terms of time 
frame.  
To investigate time-specific mortality, articles were grouped by follow-up 
outcome reporting time point. Articles that reported outcomes less than or equal to three 
months were included in the three-month reporting category to summarize ‘early’ 
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mortality. Articles that reported outcomes greater than three months to six months were 
included in the six-month reporting category. Articles that reported outcomes greater than 
six months were included in the 12-month reporting category. Of articles reporting 
outcomes at three, six, and 12 months, pooled mortality was 23% (95% CI; 14-35%), 
23% (95% CI; 14-33%), and 25% (95% CI; 17-33%), respectively (Figure 2.3). There 
was significant heterogeneity (I2 = 95%; p<0·01) for all outcome reporting timepoints. 




There was no marked heterogeneity in mortality between outcome reporting timepoints 
(p=0·60), but it was included in the pooled analysis resulting in a pooled mortality of 
24% (95% CI; 19-29%).  
Mortality endpoints by HIV status  
Seven studies reported mortality for HIV-positive adults. For HIV positive adults, 
pooled mortality was 57% (95% CI; 48-67%), compared with 16% (95% CI; 10-24%) in 
HIV-negative adults (Figure 2.4). HIV status explained a significant amount of the 
observed heterogeneity in TB meningitis mortality (p< 0·01).  




Mortality endpoints by geographical region 
Most studies reporting on TB meningitis mortality were conducted in India and 
the Asian continent (n=27; 70%) where pooled mortality ranged from 2-67% (Figure 
2.2). The countries reporting the highest TB meningitis mortality were located in sub-
Saharan Africa where mortality ranged from 23-80%. Continent (Africa vs. Asia) 
explained a significant amount of the observed heterogeneity in TB meningitis mortality 
(p=0.02). 




Temporal variation in mortality endpoints 
To investigate changes in TB meningitis treatment outcomes over time, we 
conducted a temporal analysis in which individual studies were allocated to one of five 
time periods and stratified analyses conducted. Time periods were sub-divided into five-
year windows from 1995 onwards, and pooled mortality analyzed within each time 
window. Highest pooled mortality was 31% (95% CI; 14-51%) in articles published from 
2006-2010, though there was no significant variation by time window (Figure 2.5).  In 
earlier time periods, the heterogeneity in survival was greatest and heterogeneity appears 
to have reduced in the more recent time periods.  
Neurological disability 
Functional outcomes among survivors was a pre-specified endpoint in 24 studies; 
10 studies reported on functional outcomes using the modified Rankin Scale score (n=6) 
or the Barthel index (n=5), and 10 studies reported on neurocognitive disability without 
using a specified scale or measurement tool, and five studies reported using “clinical 
assessments”.   
The timing and method of neurological assessments varied between studies; the 
most commonly used outcome assessment being physical disability conducted at the end 
of follow up. In this analysis, participants were considered disabled if there was any 
indication of functional disability as reported by the modified Rankin Scale or Barthel 
Index. Of the studies utilizing the modified Rankin Scale, the pooled proportion of 
patients experiencing some level of physical disability was 26% (95% CI; 18-35%) with 
considerable heterogeneity (Figure 2.6). Of the studies using the Barthel Index the 
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proportion of patients experiencing some level of physical disability was 32% (95% CI; 
22-43%) with only moderate heterogeneity. 
 
Discussion  
In this rigorous systemic review and meta-analysis, we reviewed treatment 
outcomes for over six thousand adults with TB meningitis, and our data clearly 
demonstrate that the mortality and neurological sequelae associated with TB meningitis 
remains unacceptably high. Although there was significant heterogeneity between studies 
(I2 >95%), overall risk of death was 23% at three months, and 25% at 12 months. In 
patients that did survive, neurological sequelae were common, affecting nearly one third 
of all patients. Furthermore, our temporal analysis of treatment outcomes indicate that 
prognosis has improved little over time. Our results are in concordance with two recently 
Figure 2.6. Physical Disability by Modified Rankin Scale and Barthel Index 
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published systematic reviews which reported overall morality associated with adult TB 
meningitis to be 23% and 25%, and risk of neurological sequelae to be 29% and 50%, 
respectively. Our study expands on the current literature through sub-group meta-
analyses to evaluate differential treatment outcomes by HIV status and geographical 
region. 
We have demonstrated that patients with HIV-associated TB meningitis have 
three-fold higher mortality compared to HIV-negative cohorts; mortality in HIV-negative 
cohorts ranged between 10-24% compared to 48-67% in HIV-positive cohorts (p< 0.01). 
Pathogenesis research is urgently needed to investigate the disproportionate mortality 
associated with HIV co-infection in TB meningitis, and to identify potential interventions 
or preventative measures.  
Secondly, our data demonstrate that despite adoption of standardized treatment 
regimens for TB meningitis, considerable global disparities in treatment outcomes exist. 
Pathogenesis work has shown that even within a Vietnamese population a single genetic 
polymorphism significantly impacts on corticosteroid responsiveness and survival from 
TBM.79 The extent of the heterogeneity observed in this meta-analysis raises the 
possibility that genetic or other latent factors may contribute to outcome and the current 
one-size-fits all approach to treatment may be effective in some individuals/populations 
and less effective in others. Our sub-group meta-analyses indicate that patients in the 
African continent have a higher mortality compared to all other continents. This may in 
part be explained by the higher co-prevalence of HIV. However, given the considerable 
resource limitations including a lack of intensive care facilities typical of many settings in 
sub-Saharan Africa, it is likely that the management of commonly encountered 
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complications of TB meningitis including hyponatremia, raised intracranial pressure, 
hydrocephalus, stroke, and nosocomial infections are suboptimal. Further research is 
needed to determine the attributable mortality due to a lack of supportive or critical care 
in sub-Saharan Africa. Our systematic literature review highlights the historical paucity 
of clinical studies published from this continent. In order to address the devastatingly 
poor outcomes from HIV-associated meningitis, particularly for those in sub-Saharan 
Africa, we need to design, fund and deliver more clinical research.  
Our meta-analyses of follow-up time-specific mortality at three, six, and twelve 
months, highlight that over 90% of TB meningitis deaths occur in the first three months. 
This may justify that three-month mortality is a reasonable RCT endpoint, potentially 
making study trial follow-up shorter and cheaper, and therefore accelerating research 
outputs. However, the considerable heterogeneity found in these analyses as well as 
inconsistencies in reporting outcomes, indicates that further evidence is needed to justify 
a three-month clinical trial endpoint.  Clinical studies to identify drivers of early mortality 
in TB meningitis may inform the design of treatment intensification strategies and other 
adjunctive interventions.  
Concerningly, our results demonstrate that minimal improvements in survival 
have been made over time. There are a number of temporal factors which may have 
affected outcomes in certain time periods including the height of the HIV epidemic in the 
1990-2005 period, ART  rollout in the 1995 to 2010 windows, the increasing availability 
of more rapid diagnostics in the form of the Xpert MTB/Rif assay in 2010 to 2020 
windows facilitating the diagnosis of TB meningitis where it was previously 
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unconfirmed, and lastly gradually increasing rates of anti-TB drug resistance worldwide. 
Reporting bias, which may have varied over time, must also be considered.  
Our analysis has several limitations. Firstly, although we only included studies 
which employed a pre-specified diagnostic criterion for TB meningitis, there was 
considerable variation in the quality of diagnostic criteria used, and diagnostics have 
changed over time. We chose not to restrict diagnostic criteria to microbiologically 
confirmed TB meningitis, because doing so would have restricted our meta-analysis to 
40% (n=2,243) of adults, and furthermore we wanted our results to be generalizable to 
real world clinical settings where confirmation rates are often only moderate. We do 
however recognize that misclassification of undifferentiated meningitis cases as TB 
meningitis is common, especially when left to physician discretion; as may have been the 
case in some of the patients included in our meta-analysis and therefore this would 
undermine the accuracy of our outcome estimates. Secondly, in the spirit of 
generalizability we chose to include case-series, which are primarily descriptive and not 
wholly representative of the populations they are drawn from. Although this may have 
posed some unmeasurable bias, we believe that this would not have substantially 
impacted our results since mortality and neurological sequelae, our outcomes of interest, 
would not have measured differently or changed based on study design. Thirdly, the 
specific anti-TB regimen utilized and drug resistance rates within the cohorts was 
inconsistently reported in studies therefore we were unable to conduct stratified meta-
analyses based on drug resistance patterns. The International Tuberculous Meningitis 
Research Consortium paper on standardized methods for enhanced quality and 
comparability of TB meningitis studies, specify that it is essential to document the dose, 
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route of administration, and duration of all anti-TB drugs used in TB meningitis studies.80 
There remain several outstanding questions concerning the optimal treatment of TB 
meningitis, and therefore to facilitate cross study comparisons and interrogate differences 
in study outcomes basic information about the treatment provided is essential.  
Finally, there was a considerable lack of standardization of reporting on treatment 
outcomes. This was particularly marked with respect to reporting of neurological 
sequelae; firstly, neurological sequalae were rarely reported (only 10/39 (26%) studies 
including any data on neurological sequalae), the tools used were inconsistent (nine tools 
in total) and the time-points for assessment were rarely reported. This inconsistent 
reporting hampered comparison of data across studies. Given the importance of 
neurological disability in TB meningitis and the importance of developing a standardized 
evidence base against which to assess new treatments, the International Tuberculous 
Meningitis Research Consortium recommend that the modified Rankin Score should be 
used as the first line tool, which should be recorded at 12 months from antituberculosis 
treatment initiation in all adults.80 We support this recommendation, and in addition 
would suggest that mortality be routinely reported on at three, six, and 12 months if 
possible, to improve study comparability.  
The strengths of this work include its size, with 39 individual studies included 
studies from Asia, Africa, Europe and the Americas making our estimates broadly 
generalizable to a range of settings. Our systematic review is larger than two previously 
published systematic reviews of adult TB meningitis.29,30 In comparison to Wen et al,29 
we decided to include randomized control trials in our systematic review which enable us 
to include the highest quality of trial evidence, and we also reported drug resistance rates 
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within each included study. In comparison to Wang et al,30 we ascertained variation in 
treatment outcomes geographically, and reported on the nature and severity of reported 
neurological sequelae. Overall, we assessed a wide range of co-variates to investigate the 
heterogeneity in treatment outcomes observed. To our knowledge, this is the most 
extensive critical appraisal of TB meningitis outcomes to date.  
In conclusion, adult TB meningitis is associated with considerable neurological 
morbidity and mortality and remains a major challenge in TB endemic regions. The worst 
outcomes are observed by those with HIV co-infection in sub-Saharan Africa where risk 
of death is three-fold higher. Our study was limited by suboptimal reporting on diagnostic 
criteria utilized, drug resistance rates, details of treatment regimens used, as well highly 
variable outcome reporting. Adoption of standardized reporting systems across TB 
meningitis studies would not only facilitate across study comparisons, but overall would 
also improve the quality of research outputs and support collaborative research across 
centers with an aim of improving TB meningitis outcomes globally.  
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CHAPTER 3. MANUSCRIPT 2: DEVELOPMENT AND VALIDATION OF A 




Tuberculosis remains a major global health problem, and tuberculous (TB) 
meningitis is the most lethal and disabling form, representing more than 100,000 new 
cases each year.81 Current diagnostic evaluations are lengthy, inaccessible, or insensitive 
leading to delayed diagnosis and treatment – significant risk factors for poor outcomes.81 
Ziehl-Neelsen staining of CSF has low sensitivity in most settings, and mycobacterial 
culture is typically too slow to inform treatment decisions. While recently introduced 
nucleic acid amplification tests (NAATs) have the potential to speed up diagnosis, 
variable sensitivity in clinical settings means that negative tests are often insufficient to 
justify withholding treatment.9 Furthermore, there is a disproportionate burden of TB 
meningitis in low-resource settings, where access to NAATs is limited. An additional 
barrier to increased knowledge regarding the true prevalence, incidence, and mortality of 
TB meningitis as well as the evaluation of novel diagnostics is the lack of an agreed 
reference standard that is 100% accurate in all settings.9  
One approach to improving rapid diagnosis of TB meningitis is to develop and 
validate multivariable prediction models (MPM) for clinical use. At least 10 MPM for TB 
meningitis have been developed, which tend to perform well in internal validation but 
poorly when externally validated in different settings or populations. The primary 
contributing factor of heterogeneous model performance across different settings and 
populations is case mix variation, which refers to the distribution of important predictor 
variables such as HIV status, age, and the prevalence of TB meningitis. Case mix 
variation across different settings or populations can lead to genuine differences in the 
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performance of a prediction model, even when the true predictor effects are consistent 
(that is, when the effect of a particular predictor on outcome risk is the same regardless of 
the study population).25 Prior MPMs for the diagnosis of TB meningitis were all 
developed from a single study or population, and therefore have not adequately 
accounted for case-mix variation, compromising external validity and clinical utility. 
 Furthermore, most approaches to MPM development utilized logistic regression 
with stepwise (backwards or forwards) selection of variables into the model, which were 
retained if they significantly predicted TB meningitis diagnosis (determined a priori with 
a set p-value threshold). This methodological approach has many limitations including 
overfitting and the inability to model non-linear associations, including interactions, 
without pre-specifications.82-84 Using this approach does not adequately model case-mix 
variation, which can also lead to overfitting.83  
To overcome these limitations, we collected individual participant data (IPD) 
from multiple studies in a variety of geographical locations and evaluated alternative 
modeling approaches. IPD is preferred to aggregate data meta-analysis as multiple 
individual level factors related to the disease can be examined in combination.85 The 
coalition and synthesis of IPD offers a novel and natural opportunity to overcome the 
challenge of external validation of previously published MPMs. Recent studies have 
shown how big data can be used by researchers to examine heterogeneity and improve 
the predictive performance of a model across different populations, settings, and 
subgroups.86-88 Therefore, in addition to logistic regression we also analyzed the data 
using machine learning techniques, classification and regression tree (CART) and 
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random forest models. Our findings are reported in accordance with the transparent 
reporting of a MPM for individual prognosis or diagnosis (TRIPOD) statement.89 
Methods: 
Literature Search Strategy 
This review was carried out according to the Preferred Reporting Items for 
Systematic review and Meta-Analysis of IPD (PRISMA) guidelines.90 Our protocol is 
available on Wellcome Open Research 
(https://doi.org/10.12688/wellcomeopenres.15056.2). A systematic electronic search was 
conducted using MEDLINE and EMBASE with the aim of identifying all studies 
reporting treatment outcomes in adult tuberculous meningitis from 1990 to present. This 
time period corresponds to the WHO recommendation of standard quadruple therapy for 
the treatment of tuberculosis.26 Controlled and natural language terms identified key 
search concepts such as: “tuberculosis”, “meningitis”, “mortality”, “complications” and 
“outcome.” Full search strategies are presented in Appendix C. Searches were conducted 
on 26 September 2018.   
Study Selection 
The following exclusion criteria were applied; (i) studies published before 1990; 
(ii) case-control studies and case-series of patients with confirmed TBM (iii) studies not 
written in English; (iv) studies where IPD are not available; (v) mathematical modeling 
studies; (vi) any systematic review superseded by an updated systematic review; (vii) 
studies which collected insufficient data on lab and clinical variables known to predict 
TB meningitis (viii) studies of participants less than 5 years old. 
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Studies were eligible for inclusion if they both (i) employed any of the following 
study designs: cross-sectional study, cohort study, randomized controlled study; (ii) 
systematically evaluated a sample of patients with suspected TB meningitis with at least 
one of, Ziehl–Neelsen stain, commercial NAAT for mycobacterium tuberculosis, or 
mycobacterial culture of CSF.  
A two-stage screening process was employed: title and abstracts were screened 
for eligibility by two researchers; and those considered potentially eligible underwent full 
review by one researcher. 
Risk of bias of included studies was assessed by two independent reviewers using 
QUADAS-2,91 discrepancies were resolved by a third reviewer. 
Data Acquisition and Synthesis 
 Corresponding authors of studies identified as eligible after full text review were 
contacted with a request to provide anonymized IPD. A data sharing agreement was 
signed before eligible authors uploaded the IPD file to an encrypted and secure cloud 
storage repository. Uploaded IPD files were harmonized, units were standardized, and 
data were synthesized in R studio. Specific IPD variables requested are listed in Table 
3.1 and were chosen to include as much information about the participants as possible. Of 
these variables, we identified 11 target predictors based on prior studies (Table 1.2): 
symptom duration, cerebral spinal fluid (CSF) white blood cell (WBC) count, CSF WBC 
differential, CSF glucose, CSF protein, blood glucose, blood WBC count, HIV status, 
age, and biological sex. Subjects who were missing more than 50% of target predictors 
were excluded. Datasets were excluded if there was a clear pattern of missingness among 
the target predictors that was based on diagnosis, age, sex, or some other participant  
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characteristic. IPD that were provided from the same research group were analyzed as a 
single dataset. 
 Multiple Imputation  
Blood glucose was the variable with the most missingness in every dataset. We 
performed single imputation of the median value in each dataset for missing blood 
glucose. For the other target predictors, the MICE package in R studio was used to 
impute missing values within each dataset prior to merging. Missing data within datasets 
Clinical Data at Presentation  Blood Results CSF Results 
• Age* 
• Sex* 
• Presence of seizures 
• Presence of neck stiffness 
• Duration of symptoms* 
• Focal neurological deficit 
(including cranial nerve palsy) 
• Temperature 
• Glasgow Coma Scale (GCS) 
 
• HIV status* 
• White Blood cell 
count 




• WBC Count* 
• Total or % neutrophils* 
• Total or % lymphocytes* 
• Protein* 
• Glucose* 
• Gram stain 
• Adenosine deaminase activity 
• Bacterial culture 
• India ink stain 
• Cryptococcal antigen or 
culture 
• Microscopy for acid-fast 
bacilli 
• Mycobacterial culture 
• NAAT for Mycobacterium 
tuberculosis 
• NAAT for any virus 






• Urine LAM 
• Microscopy for acid-fast 
bacilli 
• Mycobacterial culture 
• NAAT for Mycobacterium 
tuberculosis 
• Chest X-ray 
• Abdominal 
ultrasound scan 
• CT brain 
• MRI brain 
• Outcome (Discharged or 
Died) 
• Date of Outcome 
 
*Target predictors 
LAM, lipoarabinomannan; NAAT, nucleic acid amplification test 
 





were assumed missing at random. A total of 50 imputations were used per missing 
variable. The fraction of missing information (FMI) statistic was obtained in the 
modeling step to assess efficiency gains.92  
Data Analysis 
We summarized IPD from each of the studies using medians and proportions for 
continuous and dichotomous data, respectively. We defined ‘confirmed’ TB meningitis as 
having any of the following positive tests in the CSF: Xpert MTB/RIF (Cepheid, 
Sunnyvale, CA), Xpert Ultra MTB/RIF, other PCR, culture, acid fast bacilli (AFB), or 
‘definite’ TB meningitis classification per the Uniform TBM case definition.10 We 
defined ‘probable’ TB meningitis as having no alternate diagnoses and any CT, MRI, or 
X-ray suggestive of TB meningitis or a ‘probable’ TB meningitis case classification per 
the Uniform TB meningitis case definition.10 In these analyses, participants that fit the 
criteria for confirmed or probable TB meningitis were considered a TB meningitis case. 
Three algorithm development strategies were employed to predict a binary 
outcome: TB meningitis cases vs. non-TB meningitis. First, an IPD meta-analysis using a 
logistic regression model with stratified intercepts for each country was fitted with the 
selected 11 target predictors.87 We employed a backwards stepwise method for predictor 
selection using a p-value threshold of 0.1. We also fitted a logistic regression model 
without stratified intercepts. Next, we developed CART and random forest models with 
machine learning methods with the same 11 target predictors as well as a variable for 
country.  
All models were internally validated using an k-fold internal-external cross-
validation (IECV) approach, which is a multiple validation approach that accounts for 
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multiple datasets by rotating which are used toward model development and validation.87 
We amalgamated IPD from studies that originated from the same working group into a 
single IPD dataset. During the IECV process, each IPD dataset was excluded from the 
available set, and the remainder was used to develop the MPMs; the excluded dataset was 
then used to validate the model externally. This process was repeated with each dataset 
being omitted in turn, allowing the consistency and performance of the developed MPM 
to be examined across multiple datasets. We measured performance in each study (fold) 
using the calibration ratio of predicted (expected) to observed outcomes (denoted by 
E/O), calibration plots (intercept and slope), the area under the receiver operating 
characteristic (ROC) curve, and the Brier Score.87,93,94 Good model performance is 
reflected by the E/O ratio, calibration slope, and ROC values being close to one. We 
summarized overall MPM internal validity by averaging the values of ROC and 
amalgamating calibration across the folds in addition to calculating the Brier score. The 
Brier score is a measure of the accuracy of probabilistic predictions where a value close 
to 0 indicates perfect accuracy.  
Additionally, we calculated sensitivity (SE), specificity (SP), positive predictive 
value (PPV), negative predictive value (NPV), false positive rate (FPR), false negative 
rate (FNR), positive likelihood ratio (LR+), negative likelihood ratio (LR-), and 
proportion correctly classified (PCC) in each IPD dataset fold along different prediction 




Search results, studies, and participants included 
After removal of duplicates, our searches yielded 2179 reports that underwent title 
and abstract screening, and 121 full texts were reviewed (Figure 3.1). 34 studies met our 
eligibility criteria for inclusion, and we acquired IPD from 19 studies (18 datasets) with a 
total of 6,147 individual participants. Four datasets (N=796 individual participants) were 






















































Studies iden fied  through database
searching 
(n = 2192)
Studies a er duplicates removed 
(n= 2179)





Full-text studies assessed for
eligibility 
(n = 121)
Full-text studies excluded (n = 87)
Inadequate clinical data collection (n = 73)
Case-controlled study (n = 10)
Case series of confirmed TBM only (n = 2)
Did not perform reference standard tests (n = 1)
Data republished in subsequent paper (n = 1)
Studies for which IPD was sought
(n = 34)
Individuals for which IPD was
sought 
(n = 10607)
Studies (n = 15) for which IPD (n = 4460) was not
provided
Corresponding author did not respond to emails (n = 15)
(IPD = 4460)




Studies excluded after evaluation of the data
provided (n = 4)
Clear pattern of missingness (n = 2)
Key predictors missing >50% of data (n = 2)
Individuals excluded after evaluation of data
provided (n = 1671)
Less than 5 years old (n = 82)
Missing >50% of key predictors (n = 1589)
Studies included in analysis 
(n = 15)
Individuals included in analysis 
(n = 3671)
Figure 3.1. PRISMA IPD Flow Diagram of Study Selection Process 
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or target predictors were missing >50% of their data. An additional 82 participants less 
than five years old and 1,589 participants missing >50% of key predictors were excluded.  
The final analysis dataset included 3,671 individual participants from 15 different 
studies (Table 3.2). Four studies originated in Brazil95-98 (N= 101, 321, 289, and 92), 
three from Vietnam99-101 (N=160, 303, and 204), two from South Africa (N=93 and 36) 
102,103, and one each from Uganda104 (N=611) Botswana105 (N=138), Indonesia33 
(N=761), Morocco18 (N=414), Peru106 (N=37), and Romania107 (N=111). The studies 
conducted by Nhu,99 Heemskerk,100 and Donovan101 in Vietnam, and the studies 
conducted by Boulware103 and Rhein104 in Uganda originated from the same working 
groups. Most were cohort studies (n=9) or cross-sectional studies (n=4), and two were 
randomized controlled trials. The risk of bias assessment is summarized in Appendix D. 
No study showed high risk of bias. 
A total of 1148 (31%) participants met the case definition for confirmed TB 
meningitis and 104 (3%) met the case definition for probable TB meningitis. Of the non-
TB meningitis cases, 13% had cryptococcal, 6% had bacterial, and 3% had viral 
meningitis. Most participants had an unknown diagnosis (Figure 3.2). The age range of 
participants was between 5 to 90 years old and was statistically significantly different 
between TB and non-TB meningitis groups (Table 3.3). Among datasets that disclosed 
biological sex or gender, 58% (n=1746) of participants were men. There was no 
difference in biological sex or gender between TB and non-TB meningitis groups. With 
the exception of the dataset provided by Dendane et al.18, at least 10% of participants 
were HIV-positive in each study. The final analysis dataset included 1644 (45%) HIV 
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positive individuals. There was a higher proportion of HIV-positive individuals in the 

















Anselmo95 2017 Brazil High 
Cross-
Sectional 
289 43 (6-84) 163 (56) 142 (49) 10 (3.5) 39 (13) 
Gualberto96 2017 Brazil High Cohort 92 37 (8-64) 65 (71) 92 (100) 6 (6.5)  8 (8.7) 
Azevedo97 2018 Brazil High Cohort 101 40 (17-73) 62 (61) 101 (100) 0 (0) 12 (12) 
de Almeida98 2019 Brazil High 
Cross-
Sectional 
321 40 (5-86) 188 (59) 177 (55) 13 (4.0) 13 (4.0) 
Nhu99 2014 Vietnam High 
Cross-
Sectional 
160 NA NA 64 (40) 24 (15) 132 (83) 
Heemskerk100 2018 Vietnam High Cohort 303 NA NA 38 (13) 0 (0) 70 (23) 
Donovan101 2020 Vietnam High Cohort 204 NA NA 43 (21) 0 (0) 113 (55) 
Jarvis105 2019 Botswana Low 
Cross-
Sectional 
138 38 (5-90) 80 (58) 97 (70) 3 (2.2) 7 (5.1) 
van Laarhoven33 2017 Indonesia High Cohort 761 30 (14-78) 460 (60) 146 (19) 0 (0) 339 (45) 
Dendane18 2013 Morocco Low Cohort 414 32 (14-84) 221 (53) 1 (0.2) 0 (0) 246 (60) 
Metcalf106 2018 Peru Low Cohort 37 40 (19-77) 27 (73) 23 (62) 11 (30) 8 (22) 
Jipa107 2017 Romania Low Cohort 111 34 (18-75) 57 (51) 32 (29) 0 (0) 20 (18) 






RCT 61 35 (19-75) 37 (61) 58 (95) 4 (7) 31 (51) 
Rhein104 2019 Uganda Low RCT 586 34 (14-75) 343 (59) 581 (99) 24 (4) 98 (17) 
TOTAL     3671 35 (5-90) 1746 (58) 1644 (45) 104 (2.8) 1148 (31) 
*RCT = Randomized controlled trial 
 










Table 3.3. Univariate analysis of clinical, hematological, and CSF data of individual 







 Median (IQR) 
or N (%) 
Median (IQR) 
or N (%) 
 
Age, years 35 (27-46) 32 (25-43) <0.001 
Men 1,229 (59) 517 (57) 0.260 
Symptom Duration, days 7 (4-21) 11 (6-20) <0.001 
Fever 1,298 (54%) 871 (70%) <0.001 
HIV-positive 1,225 (51%) 419 (34%) <0.001 
Blood Glucose, mg/dL 103 (94-113) 104 (84-120) 0.477 
CSF WBC count, cells/mm3 8 (2.5-139) 140 (40-319) <0.001 
WBC Differential   <0.001 
    WBC < 5 cells/mm3 1,105 (46) 125 (10)  
    Neutrophilic Dominance 373 (15) 332 (27)  
    Lymphocytic Dominance 941 (39) 795 (64)  
CSF Protein, mg/dL 60 (31-134) 154 (86-267) <0.001 
CSF Glucose, mg/dL 53 (37-68) 23 (5.5-41) <0.001 
CSF CrAg Positive 455 (19) 13 (1) <0.001 
*p-value based on chi-square or Kruskal-Wallis Rank Sum test 
 
 
Figure 3.2. Meningitis Etiologies of Participants 
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Multivariable Prediction Models 
  Backwards stepwise predictor selection revealed CSF WBC count, CSF WBC 
differential, CSF glucose, blood glucose, HIV status, and CSF cryptococcal antigen 
(CrAg) as significant predictors of TB meningitis (Table 3.4). Stratified intercepts for 
each country (with Brazil as 
the reference group) indicated 
significant heterogeneity in 
predictors from Indonesia, 
Morocco, Peru, South Africa, 
Uganda, and Vietnam, with an  
overall increased odds of TB 
meningitis in these countries 
(Table 3.4). A logistic 
regression model without 
stratified intercepts for 
country is presented in 
Appendix E. 
 With the exception of symptom duration, blood WBC count, age, and biological 
sex, all key predictors were used in the development of both CART and random forest 
models. Symptom duration, blood WBC count, age, and biological sex were excluded 
due to complete missingness within datasets, which could not be imputed. The resulting 
CART decision tree is shown in Figure 3.3. The color gradient corresponds to predictive  
Table 3.4. Logistic Regression Coefficients 
 Covariate Odds Ratio (95% CI) 
CSF WBC count, 
100/mm3 
0.91 (0.90-0.93) 
WBC < 5 cells/mm3 0.25 (0.16-0.40) 
Neutrophilic Dominance 0.96 (0.59-1.56) 
Lymphocytic Dominance 1.00 (0.64-1.57) 
CSF Glucose, 10 mg/dL 0.67 (0.64-0.71) 
Blood Glucose, 10 mg/dL 1.07 (1.03-1.10) 
HIV-positive 1.43 (1.13-1.82) 
CSF CrAg Positive 0.02 (0.01-0.04) 
Botswana 0.62 (0.32-1.29) 
Indonesia 2.77 (2.02-3.80) 
Morocco 5.04 (3.15-8.09) 
Peru 2.68 (1.26-5.72) 
Romania 0.89 (0.50-1.60) 
South Africa 2.41 (1.43-4.07) 
Uganda 4.93 (3.44-7.08) 







probability of TB meningitis with 
green representing higher 
probability of TB meningitis and red 
representing lower probability of TB 
meningitis. The random forest model 
indicated that CSF glucose, CSF 
WBC count, CSF protein, and blood 
glucose were the most important 
variables used in model 
development (Appendix F). 
Internal-External Cross-Validation 
 Model performance was assessed in each of the 12 datasets (folds) left out in the 
IECV process. All MPMs demonstrated poor calibration in each fold (Table 3.5). The 
CART MPM had the widest range of E/O and ROC values, indicating inconsistent 
performance across the study IPD. Additionally, CART had the lowest range of ROC 
values  (0.60-0.84), indicating a weaker discriminatory power than logistic and random 
forest models. Performance was worst across all three models for Metcalf.106 
Performance was consistent across all three MPMs for Azevedo,97 Gualberto,96 
Dendane,18 and the Uganda dataset103,104 indicating clearer distinction between TB and 
non-TB meningitis cases (lower heterogeneity). Performance was most inconsistent in 



































van Laarhoven,33 Bateman,102 Jipa,107 the Vietnam dataset99-101  indicating more 
heterogeneity in TB meningitis cases and non-cases. 
Overall discriminatory 
power measured by the mean 
area under the ROC curve 
was similar across MPMs, 
with a ROC value of 0.79 
(95% CI; 0.75-0.83) for 
logistic, 0.76 (95% CI; 0.71-
0.80) for CART, and 0.81 
(95% CI; 0.76-0.85) for 
random forest (Figure 3.4). 
Test Dataset Logistic  CART  Random Forest 
 E/O Slope ROC  E/O Slope ROC  E/O Slope ROC 
van 
Laarhoven33 0.07 -0.45 0.77 
 
1.15 0 0.60 
 
0.98 0.49 0.89 
Bateman102 1.87 0.73 0.79  1.03 0.23 0.73  0.90 0.35 0.83 
Jipa107 0.05 -0.22 0.90  2.75 0.07 0.79  1.85 0.70 0.66 
Azevedo97 0.17 -0.20 0.79  0.08 -0.30 0.84  0.42 0.09 0.86 
de Almeida98 0.58 0.05 0.74  2.15 0.06 0.79  1.31 0.19 0.72 
Anselmo95 0.04 -0.44 0.66  0 -0.39 0.80  0.02 -0.44 0.84 
Gualberto96 0.50 -0.02 0.88  0.29 -0.07 0.77  0.71 -0.03 0.89 
Metcalf106 0.21 -0.59 0.64  1.00 -0.33 0.61  0.84 -0.09 0.65 
Dendane18 0.05 -0.23 0.85  1.28 0.06 0.83  1.21 0.35 0.82 
Vietnam99-101 0.08 -0.33 0.84  0.73 0.17 0.68  0.64 0.54 0.85 
Uganda103,104 0.24 0.06 0.85  0.60 0.04 0.79  0.49 0.29 0.83 
Jarvis105 0.40 -0.09 0.78  2.30 0.09 0.83  2.00 0.05 0.85 
            
Figure 3.4. ROC Curves for Logistic, CART, and 
Random Forest MPMs 
 
Table 3.5. Internal-External Cross-Validation Multivariable Prediction Model 
























Model − ROC (95% CI)
Logistic − 0.79 (0.75−0.83)
CART − 0.76 (0.71−0.80)
Random Forest − 0.81 (0.76−0.85)
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The Brier score was also similar across the three models with the logistic model 
performing only 0.03 points above the CART MPM. Conversely, calibration was varied 
between the MPMs. The logistic MPM had the worst calibration with the E/O ratio and 
slope values furthest from one compared to the CART and random forest MPMs (Table 
3.6). Of the three models, calibration slope was closest to one for the random forest 
model (0.59). Visual inspection of the calibration plots for all three MPMs shows a clear 
hierarchy of calibration performance with random forest outperforming both logistic and 
CART MPMs (Figure 
3.5). Random forest 
had the most bin 
midpoints falling along 
a 45-degree line (grey 
dotted line), 
demonstrating that the 
number of TB 
meningitis cases 
increases as prediction 
probability increases. 
Table 3.6. Overall Performance of Logistic, CART, and Random Forest MPMs 
MPM 
Overall Calibration  Brier 
Score 
ROC (95% CI) 
Ratio (E/O)1 Intercept Slope 
Logistic 0.16 30.6 0.45 0.19 0.79 (0.75-0.83) 
CART 0.99 18.4 0.32 0.16 0.76 (0.71-0.80) 
Random 
Forest 
0.86 14.9 0.59 0.15 0.81 (0.76-0.85) 


































Figure 3.5. Calibration Plot for Logistic, CART, and 
Random Forest MPMs 
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CART was the most poorly calibrated model with the widest confidence intervals and no 
observed events falling in the 50-bin midpoint (Figure 3.5).   
Diagnostic utility of each MPM is summarized in Tables 3.7-3.9. At the pre-
determined prediction probability cutoff of 0.1, sensitivity and specificity were 0.84 (95% 
CI; 0.76-0.92) and 0.52 (95% CI; 0.41-0.64) for logistic regression, 0.77 (95% CI; 0.68-
0.87) and 0.59 (95% CI;0.45-0.73) for CART, and 0.89 (95% CI; 0.82-0.97) and 0.36 
(95% CI; 0.24-0.48) for random forest, respectively. The random forest MPM missed the 
fewest number of TB meningitis cases with a FNR of 0.11 (95%CI; 0.03-0.18), compared 
to the logistic, 0.16 (95%CI; 0.08-0.24), and CART, 0.23 (95%CI; 0.13-0.32), MPMs. In 
the presence of a negative test, the logistic and random forest MPMs decreased the 
probability of TB meningitis disease by approximately 30% (LR- = 0.25, 95%CI; 0.13-
0.35 and LR- = 0.23, 95%CI; 0.11-0.35, respectively). The CART model had the highest 
proportion correctly classified with 0.69 (95%CI; 0.61-0.77) of predictions correctly 
classifying IPD as either TB or non-TB meningitis followed by logistic, 0.65 (95%CI; 










































































































































































































































































































































































































































































































































































































































































































































































































In this systematic review and IPD meta-analysis we developed and internally 
validated three unique MPMs using IPD from over three thousand adults spanning nine 
countries. Our data clearly demonstrates that heterogeneity in clinical and subacute TB 
meningitis case presentation impacts performance of MPMs for TB meningitis. Although 
we accounted for this heterogeneity in every step of MPM development – from the data 
we used to the analytical methods employed – IECV revealed that performance of the 
three MPMs varied considerably in different populations and settings. Random forest, a 
machine learning based MPM, had slightly more promise in reducing the number of 
missed TB meningitis cases with a sensitivity of 0.89 (95% CI; 0.82-0.97) and a false 
negative rate of 0.11 (95%CI; 0.03-0.18) at a threshold of 0.1. Our MPMs and internal 
validation results are in concordance with the 10 published clinical prediction tools based 
on MPMs, which showed similar significant predictors of TB meningitis and 
performance, respectively. Our study expands on the current literature through the use of 
IPD from multiple populations and settings and machine learning modeling approaches to 
improve the timeliness and efficiency of TB meningitis diagnosis. 
We have demonstrated that machine learning approaches to MPM development 
are not superior to classic MPM development approaches such as logistic regression. In 
fact, the CART MPM performed substantially worse than the logistic MPM and the 
random forest MPM performance was no different than the logistic regression MPM. 
Machine learning algorithms have been gaining popularity as an alternative approach to 
prediction and classification algorithms in clinical contexts. However, a recent systematic 
review indicates that there is, on average, no difference in the performance between 
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logistic regression and machine learning approaches.108 The strong predictive ability of 
machine learning models increase the susceptibility of over-calibration to the 
development dataset and thus impact performance external validity.108 This phenomenon 
was demonstrated in the CART MPM where over-calibration was observed in seven out 
of the twelve folds and had the worst overall performance compared to the logistic and 
random forest MPMs. Additionally, machine learning approaches tend to perform better 
when the amount of relevant information is greater than the amount of non-relevant 
information, otherwise known as the signal-to-noise ratio. In in the case of TB 
meningitis, there is a considerable amount of observed “noise” due to case-mix variation, 
lowering the overall signal-to-noise ratio. The non-inferiority in the performance of the 
logistic MPM compared to the random forest MPM demonstrates that the two machine 
learning approaches evaluated in this study do not improve prediction for TB meningitis, 
which is already challenging to diagnose.    
Secondly, our data demonstrates the significant contribution HIV-infection makes 
to case-mix variation. HIV prevalence has been identified as a significant contributor to 
heterogenous outcomes in TB meningitis and is thought to modulate pathogenesis of TB 
meningitis disease.5 All three MPMs developed in this study performed most consistently 
in IPD studies that had the entire sample either comprised of HIV-positive96,97,103,104 or -
negative persons.18 Conversely, the MPMs were most inconsistent in IPD studies with an 
HIV-prevalence range from 13-53%. Although HIV status was included in the MPMs as 
an independent predictor of TB meningitis, there remains significant heterogeneity in 
performance in IPD datasets with a mix of HIV-positive and -negative persons. In a 
separate analysis we excluded the country intercepts and found that HIV-status was no 
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longer an independent predictor of TB meningitis. This finding suggests that the country 
intercepts in the logistic regression model attempt to explain the heterogeneity induced by 
the presence of HIV-infection. Further research is needed to elucidate the relationship 
between HIV prevalence, geographic location, and TB meningitis prediction.    
While this analysis has many strengths that make it an important contribution to 
TB meningitis diagnostics, there are some limitations. It is possible that TB meningitis 
cases were misclassified as non-cases. This limitation stems from the fact that there is no 
“gold-standard” for diagnosing TB meningitis and the current diagnostic procedures have 
variable sensitivity and specificity, which is the primary motivation behind this study. We 
attempted to account for this limitation by standardizing our TB case definitions across 
the IPD studies and including cases of probable TB meningitis in the outcome. These 
steps likely captured the majority of TB cases.  
Another limitation to our analysis is missing data, including a lack of outcome 
data on all participants. Due to complete missingness of symptom duration, age, and 
biological sex in some IPD studies, these variables could not be imputed and had to be 
excluded from MPM development. Each of these variables have been indicated in prior 
MPMs as significant predictors of TB meningitis but could not be explored in this 
analysis. The lack of outcome data prevents us from conducting an efficacy validation on 
survival, which would have illustrated any reduction in mortality as a result of early 
identification of TB meningitis. Although not a limiting factor in terms of MPM 
development, it does limit our ability to show how the implementation of the MPMs 
could be useful in preventing adverse outcomes.  
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In conclusion, a machine learning based MPM does not substantially improve TB 
diagnostics over logistic regression. TB meningitis remains a difficult disease to diagnose 
with HIV status contributing to underlying heterogeneity and case-mix variation. Our 
study was limited by the available data and extensive missingness. Prioritizing the 
collection of data important to predicting TB meningitis such as CSF WBC count, 
differential, and CSF glucose could be used to better inform a MPM and are rapid, cost-
effective ways better predict TB meningitis.  
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CHAPTER 4. MANUSCRIPT 3: EXTERNAL VALIDATION OF CLINICAL 




As discussed in prior sections, a major limitation to the clinical prediction tools based 
on multivariable prediction models (MPMs) that have been developed for TB meningitis 
diagnosis is that performance is variable in different populations81 (See Table 1.2 for full 
list of prior clinical prediction tools). A clinical prediction tool developed with data from 
a Vietnamese population is currently the only one to be tested for external validity.12 This 
clinical prediction tool was originally described to be 86% sensitive and 79% specific for 
TB meningitis diagnosis in Vietnamese adults,12 and subsequent studies in Turkey,21 
Vietnam,111 India,17 China,22 and Colombia23 reported sensitivities >90% and specificities 
ranging from 50–90%.81 However, the performance of the Vietnamese clinical prediction 
tool was not generalizable to an HIV-positive cohort in Malawi, where the tool was only 
78% sensitive and 43% specific, with cryptococcal meningitis accounting for most of the 
false-positive results.24 The Uniform TB Meningitis Case Definition (UTBMCD) has 
been published to help standardize diagnostics in TB meningitis clinical research and 
enable direct comparison of studies.10 However, the UTBMCD was not designed to be 
used as a clinical prediction tool and was shown to perform poorly when used in non-
research settings.112 
In the past, clinical prediction tools have been developed with relatively small 
datasets, which likely does not capture the complexities of predictor selection, limits the 
types of model approaches that are feasible, and/or leads to the model overfitting the 
data.113 This not only has implications for internal validity but also impacts the ability for 
a model to be externally valid. To overcome this challenge, we have addressed sources of 
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bias in every step of model development from inclusion of data from different 
populations/settings to internally-externally cross-validating (IECV) the model with each 
external dataset we include (Manuscript 2). Externally validating the clinical prediction 
tool can further evaluate its diagnostic performance and demonstrate its clinical utility in 
various settings and populations.  
The aim of this study is to assess performance of the MPMs developed in 
Manuscript 2 with data from an external cohort not used in the development of the 
MPMs. Additionally, we evaluated performance along different prediction probability 
thresholds to accomplish two different goals. First, we determined the prediction 
probability threshold that maximizes sensitivity in order to more efficiently rule out TB 
meningitis. This is important because most confirmatory diagnostic tests for TB 
meningitis lack sensitivity to rule out TB meningitis, which can miss cases of TB 
meningitis and further delay treatment. Secondly, we identified the probability thresholds 
for which we could categorize clinically actionable next steps, such as the threshold for 
which TB meningitis can be ruled out, when clinicians should seek confirmatory testing 
(e.g., Gene Xpert, TB culture, etc.), and the threshold for which clinicians can 
immediately begin anti-TB meningitis treatment. This will also improve efficiency and 
help guide clinical decision making.  
Methods  
We attained screening data from a multisite, observational cohort based in Uganda 
entitled, Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related 
Meningitis (DINEOUT). Participants were included if they had complete data for the 
predictors included in the clinical prediction tool developed in Manuscript 2: cerebral 
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spinal fluid (CSF) white blood cell (WBC) count, CSF WBC differential, CSF glucose, 
CSF protein, blood glucose, HIV status, and CSF cryptococcal antigen (CrAg) test 
results. We performed single imputation of the median value for missing blood glucose. 
We defined ‘confirmed’ TB meningitis as having any of the following positive tests 
in the CSF: Xpert MTB/RIF (Cepheid, Sunnyvale, CA), Xpert Ultra MTB/RIF, other 
PCR, culture, acid fast bacilli (AFB), or ‘definite’ TB meningitis classification per the 
Uniform TBM case definition.10 We defined ‘probable’ TB meningitis as having no 
alternate diagnoses and any CT, MRI, or X-ray suggestive of TB meningitis or a 
‘probable’ TB meningitis case classification per the UTBMCD.10 
Data Analysis  
Baseline clinical characteristics and demographic data was compared by TB 
meningitis case status using chi-squared or non-parametric methods as indicated. We 
assessed diagnostic performance using calibration ratio of predicted (expected) to 
observed outcomes (denoted by E/O), calibration plots (intercept and slope), the area 
under the receiver operating characteristic (ROC) curve, and the Brier Score.87,93,94 We 
calculated sensitivity (SE), specificity (SP), positive predictive value (PPV), negative 
predictive value (NPV), false positive rate (FPR), false negative rate (FNR), positive 
likelihood ratio (LR+), negative likelihood ratio (LR-), and proportion correctly classified 
(PCC) along different prediction thresholds. All analyses were conducted in R studio.  
Results 
Participants Included  
A total of 404 participants were included in the external validation dataset from 
DINEOUT (Table 4.1). Of those, 32 (8%) participants met the case definition for 
 
58 
confirmed TB meningitis and 28 (7%) met the case definition for probable TB meningitis 
(Figure 4.1). The dominant meningitis etiology was cryptococcal meningitis (58%). The 
age range of participants was between 18 to 80 years old and was statistically 
Table 4.1. Univariate Analysis, clinical, hematological, and CSF data of individual 
participants in external validation dataset 






 Median (IQR) 
or N (%) 
Median (IQR) 
or N (%) 
 
Age, years 36 (30-43) 33 (27-39) 0.015 
Men 214 (62) 33 (55) 0.361 
Fever 155 (45) 55 (92) <0.001 
HIV-positive 332 (97) 54 (90) 0.055 
Blood Glucose, mg/dL 120 (120-120) 120 (120-120) <0.001 
CSF WBC count, cells/mm3 2.5 (2.5-31) 33 (2.5-178) <0.001 
WBC Differential   <0.001 
    WBC < 5 cells/mm3 228 (66) 23 (38)  
    Neutrophilic Dominance 4 (1) 3 (5)  
    Lymphocytic Dominance 112 (33) 34 (57)  
CSF Protein, mg/dL 84 (40-119) 11 (60-169) 0.008 
CSF Glucose, mg/dL 70 (47-90) 40 (20-76) <0.001 
CSF CrAg Positive 235 (68) 0 (0) <0.001 




significantly  different between TB and non-TB meningitis groups (Table 4.1). There 
was no difference in biological sex or gender between groups. Most participants were 
HIV-positive (N=386, 96%) and there was no significant difference in the proportion of 
HIV-positive individuals between the non-TB and TB meningitis groups (p<0.055).  
Model Performance  
 The discriminatory power measured by the mean area under the ROC curve was 
highest for logistic regression 
(0.92), followed by random 
forest (0.90) and CART (0.85) 
(Figure 4.2). All models were 
under-calibrated with E/O ratio 
values less than one (Table 
4.2). Of the three models, 
calibration slope was closest to 
one for the logistic regression 
model (0.94). Visual inspection 
of the calibration plots for all three MPMs shows that logistic regression has the most bin 
midpoints falling along a 45-degree line (grey dotted line) of observed event percentage 
indicating that logistic regression is the best calibrated MPM (Figure 4.3). CART 
Figure 4.2. ROC Curves for Logistic, CART, and 
Random Forest MPMs 
 























Model − ROC (95% CI)
Logistic − 0.92
CART − 0.82
Random Forest − 0.91
MPM Overall Calibration  Brier 
Score 
ROC  
Ratio (E/O)1 Intercept Slope 
Logistic 0.73 0.46 0.94 0.07 0.92 
CART 0.93 21.8 -0.02 0.09 0.82 
Random 
Forest 
0.70 -2.66 1.11 0.06 0.91 




remained the least calibrated 
model. Brier scores were 
very similar across the 
three MPMs (Table 4.2).  
 Diagnostic 
utility of each MPM is 
summarized in Tables 4.3-
4.5. At the pre-determined 
prediction probability 
cutoff of 0.1, sensitivity 
and specificity were 0.90 
and 0.79 for logistic regression, 0.70 and 0.81 for CART, and 0.87 and 0.73 for random 
forest, respectively. The logistic MPM missed the fewest number of TB meningitis cases 
with a FNR of 0.10 compared to the CART (FNR=0.30) and random forest (FNR=0.13) 
MPMs. In the presence of a negative test, the logistic MPM decreased the probability of 
TB meningitis disease by approximately 87% (LR- = 0.13) compared to ~40% and ~80% 
in the CART and random forest MPMs, respectively. The logistic model had the highest 
proportion correctly classified with 80% of predictions correctly classifying IPD as either 
TB or non-TB meningitis followed by CART, 79%, and random forest, 75%. 
   
 
Figure 4.3. Calibration Plot for Logistic, CART, and 






































Table 4.3. Logistic Regression Diagnostic Performance in External Validation by 
Probability Cutoff 























0 1 1 0 0.15 NA 1 0 1 NA 0.15 
0.1 0.31 0.90 0.79 0.43 0.98 0.21 0.10 4.24 0.13 0.80 
0.2 0.19 0.75 0.90 0.58 0.95 0.10 0.25 7.82 0.28 0.88 
0.3 0.16 0.70 0.94 0.67 0.95 0.06 0.30 11.47 0.32 0.90 
0.4 0.14 0.68 0.96 0.73 0.95 0.04 0.32 15.67 0.33 0.92 
0.5 0.11 0.58 0.97 0.80 0.93 0.03 0.42 22.3 0.43 0.92 
0.6 0.10 0.53 0.98 0.82 0.92 0.02 0.47 26.21 0.48 0.91 
0.7 0.08 0.42 0.98 0.81 0.91 0.02 0.58 23.89 0.59 0.90 
0.8 0.05 0.28 0.99 0.89 0.89 0.01 0.72 48.73 0.72 0.89 
0.9 0.02 0.13 0.99 0.80 0.87 0.01 0.87 22.93 0.87 0.87 
1 0 0 1 NA 0.85 0 1 NA 1 0.85 
SE, Sensitivity; SP, Specificity; PPV, positive predictive value; NPV, negative predictive value; FPR, false 
positive rate; FNR, false negative rate; LR+, positive likelihood ratio; LR- negative likelihood ratio; PCC, 
























0 1 1 0 0.15 NA 1 0 1 NA 0.15 
0.1 0.26 0.70 0.81 0.39 0.94 0.19 0.30 3.7 0.37 0.79 
0.2 0.14 0.57 0.93 0.60 0.93 0.07 0.43 8.48 0.46 0.88 
0.3 0.14 0.57 0.93 0.60 0.93 0.07 0.43 8.48 0.46 0.88 
0.4 0.14 0.55 0.93 0.59 0.92 0.07 0.45 8.23 0.48 0.88 
0.5 0.14 0.55 0.93 0.59 0.92 0.07 0.45 8.23 0.48 0.88 
0.6 0.08 0.45 0.99 0.84 0.91 0.01 0.55 30.96 0.56 0.91 
0.7 0.08 0.45 0.99 0.84 0.91 0.01 0.55 30.96 0.56 0.91 
0.8 0 0 1 NA 0.85 0 1 NA 1 0.85 
0.9 0 0 1 NA 0.85 0 1 NA 1 0.85 
1 0 0 1 NA 0.85 0 1 NA 1 0.85 
SE, Sensitivity; SP, Specificity; PPV, positive predictive value; NPV, negative predictive value; FPR, false 
positive rate; FNR, false negative rate; LR+, positive likelihood ratio; LR- negative likelihood ratio; PCC, 


























In this external validation study, we assessed the performance of three unique 
MPMs using IPD derived from a high HIV-prevalent setting. Our analysis clearly 
demonstrates predictive superiority of the logistic regression MPM compared to the 
CART and random forest machine learning approaches. The logistic MPM had better 
classification ability (ROC=0.92) and was better calibrated (slope=0.94) to the external 
validation dataset from DINEOUT. Although, the random forest MPM initially showed 
slightly more promise in reducing the number of missed TB meningitis cases in internal 
validation, poor calibration ultimately impacted external validity. Our MPMs performed 
as well as the 10 published clinical prediction tools based on MPMs, if not better.  
This analysis identified important prediction thresholds that could be used to 
guide clinical practice for diagnosing TB meningitis. Across all three MPMs, the 
























0 1 1 0 0.15 NA 1 0 1 NA 0.15 
0.1 0.36 0.87 0.73 0.36 0.97 0.27 0.13 3.17 0.18 0.75 
0.2 0.17 0.73 0.93 0.64 0.95 0.07 0.27 10.09 0.29 0.90 
0.3 0.14 0.68 0.96 0.75 0.95 0.04 0.32 16.79 0.33 0.92 
0.4 0.12 0.65 0.97 0.80 0.94 0.03 0.35 22.36 0.36 0.92 
0.5 0.10 0.57 0.98 0.81 0.93 0.02 0.43 24.37 0.44 0.92 
0.6 0.09 0.53 0.98 0.84 0.92 0.02 0.47 30.58 0.47 0.92 
0.7 0.07 0.43 0.99 0.93 0.91 0.01 0.57 74.53 0.57 0.91 
0.8 0.04 0.25 1 1 0.88 0 0.75 NA 0.75 0.89 
0.9 0.01 0.07 1 1 0.86 0 0.93 NA 0.93 0.86 
1 0 0 1 NA 0.85 0 1 NA 1 0.85 
SE, Sensitivity; SP, Specificity; PPV, positive predictive value; NPV, negative predictive value; FPR, false 
positive rate; FNR, false negative rate; LR+, positive likelihood ratio; LR- negative likelihood ratio; PCC, 




predetermined prediction probability threshold of 0.10 was the best cutoff for excluding 
non-cases while maintaining a low false negative rate across all three MPMs. The logistic 
MPM performed best at this threshold with an NPV=0.98 and LR- = 0.13, indicating that 
a negative test (predicted probability <0.1) had substantially reduced the likelihood of a 
false negative test. The optimal threshold for ‘ruling in’ TB meningitis appeared to be 
0.4, where the FPR = 0.04 and LR+ = 15.67, indicating that persons who had a positive 
test  (predicted probability 0.4) substantially increased the likelihood of actually having 
TB meningitis. In practice, these predictive thresholds could be used as a guide to inform 
diagnostic approaches to meningitis. Anyone with a predictive probability less than 0.1 
could be evaluated for another etiology and anyone with a predictive probability 0.4 
could be started on anti-TB treatment immediately. Persons with a predictive probability 
between 0.1 and 0.4 could be referred for rapid confirmatory testing, such as an NAAT. 
In this diagnostic approach, there is a strong potential to reduce the delay between 
identification and treatment by increasing efficiency and maximizing resources.  
A major strength of this analysis is the generalizability of our MPMs. Our MPMs 
showed good performance utilizing lab and clinical evaluations that are readily available 
in resource-limited settings, where the burden of TB meningitis is greatest. According to 
the WHO, blood glucose, HIV testing, and CrAg screenings are all considered essential 
diagnostics and are typically supplied in most hospitals and clinics. A full CSF evaluation 
may be harder to procure, but where there is capacity to attain a complete blood count 
and blood glucose values, there is capacity to attain these for CSF samples. In the 
absence of confirmatory diagnostic tests for TB meningitis, such as Gene Xpert or Gene 
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Xpert Ultra, our MPMs provide a tool to guide clinical decision making that can be 
utilized in most settings. 
While this study has many strengths that make it an important contribution to 
improving TB meningitis diagnostics, there are some limitations. The limitation of 
misclassification of TB meningitis persists due to inadequate diagnostics. TB meningitis 
diagnosis is determined on a case-by-case basis by the clinical staff, including physicians, 
and principal investigators, using all the available data. Thus, this limitation is mitigated 
by experience and expertise of the clinical team who manages and treats the participants 
in the DINEOUT cohort. We are confident in the case classification determined by the 
DINEOUT team and anticipate that the proportion of misclassified cases would be 
negligible and not significantly impact the overall findings of this study. Another 
limitation to this study is representation from only one setting. Having data representing 
different locations and settings to externally validate the MPMs would have provided a 
more robust ascertainment of performance across  different locations and settings. 
Finally, the DINEOUT cohort was compromised of a majority of HIV-positive persons. 
We observed in prior IECV that the MPMs performed best in cohort that were either 
comprised of mostly HIV positive or negative persons. Thus, the performance 
demonstrated in this analysis may be biased.  
In conclusion, logistic regression prevailed over machine learning methods in 
accurately predicting TB meningitis. Developing MPMs that account for case-mix 
variation due to HIV-status and geographic location have improved the overall 
performance of clinical predictions tools for TB meningitis. Our study was limited by the 
available data for external validation. Incorporating the logistic MPM into clinical 
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evaluation for TB meningitis has the potential to be a cost-effective and efficient way to 





1. WHO. Global Tuberculosis Report 2020: World Health Organization; 2020. 
2. Seddon JA, Wilkinson R, van Crevel R, Figaji A, Thwaites GE, Tuberculous 
Meningitis International Research C. Knowledge gaps and research priorities in 
tuberculous meningitis. Wellcome Open Res 2019; 4: 188. 
3. Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev 
Neurol 2017; 13(10): 581-98. 
4. Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC, Tuberculous Meningitis 
International Research C. The current global situation for tuberculous meningitis: 
epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res 2019; 4: 167. 
5. Stadelman AM, Ellis J, Samuels THA, et al. Treatment Outcomes in Adult 
Tuberculous Meningitis: A Systematic Review and Meta-analysis. Open Forum Infect 
Dis 2020; 7(8): ofaa257. 
6. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, 
still too few answers. Lancet Neurol 2013; 12(10): 999-1010. 
7. Pehlivanoglu F, Yasar KK, Sengoz G. Tuberculous meningitis in adults: a review 
of 160 cases. ScientificWorldJournal 2012; 2012: 169028. 
8. Bahr NC, Meintjes G, Boulware DR. Inadequate diagnostics: the case to move 
beyond the bacilli for detection of meningitis due to Mycobacterium tuberculosis. J Med 
Microbiol 2019; 68(5): 755-60. 
9. Boyles TH, Thwaites GE. Appropriate use of the Xpert (R) MTB/RIF assay in 
suspected tuberculous meningitis. Int J Tuberc Lung D 2015; 19(3): 276-7. 
10. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform 
case definition for use in clinical research. The Lancet Infectious diseases 2010; 10(11): 
803-12. 
11. Kumar R, Singh SN, Kohli N. A diagnostic rule for tuberculous meningitis. Arch 
Dis Child 1999; 81(3): 221-4. 
12. Thwaites GE, Chau TT, Stepniewska K, et al. Diagnosis of adult tuberculous 
meningitis by use of clinical and laboratory features. Lancet 2002; 360(9342): 1287-92. 
13. Youssef FG, Afifi SA, Azab AM, et al. Differentiation of tuberculous meningitis 
from acute bacterial meningitis using simple clinical and laboratory parameters. Diagn 
Microbiol Infect Dis 2006; 55(4): 275-8. 
14. Cohen DB, Zijlstra EE, Mukaka M, et al. Diagnosis of cryptococcal and 
tuberculous meningitis in a resource-limited African setting. Trop Med Int Health 2010; 
15(8): 910-7. 
15. Patel VB, Singh R, Connolly C, et al. Comparison of a clinical prediction rule and 
a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence 
setting. PLoS One 2010; 5(12): e15664. 
16. Hristea A, Olaru ID, Baicus C, Moroti R, Arama V, Ion M. Clinical prediction 
rule for differentiating tuberculous from viral meningitis. Int J Tuberc Lung Dis 2012; 
16(6): 793-8. 
17. Vibha D, Bhatia R, Prasad K, et al. Validation of diagnostic algorithm to 
differentiate between tuberculous meningitis and acute bacterial meningitis. Clin Neurol 
Neurosurg 2012; 114(6): 639-44. 
 
67 
18. Dendane T, Madani N, Zekraoui A, et al. A simple diagnostic aid for tuberculous 
meningitis in adults in Morocco by use of clinical and laboratory features. Int J Infect Dis 
2013; 17(6): e461-5. 
19. Zhang B, Lv K, Bao J, Lu C, Lu Z. Clinical and laboratory factors in the 
differential diagnosis of tuberculous and cryptococcal meningitis in adult HIV-negative 
patients. Intern Med 2013; 52(14): 1573-8. 
20. Qamar FN, Rahman AJ, Iqbal S, Humayun K. Comparison of clinical and CSF 
profiles in children with tuberculous and pyogenic meningitis; role of CSF protein: 
glucose ratio as diagnostic marker of tuberculous meningitis. J Pak Med Assoc 2013; 
63(2): 206-10. 
21. Sunbul M, Atilla A, Esen S, Eroglu C, Leblebicioglu H. Thwaites' diagnostic 
scoring and the prediction of tuberculous meningitis. Med Princ Pract 2005; 14(3): 151-
4. 
22. Zhang YL, Lin S, Shao LY, Zhang WH, Weng XH. Validation of thwaites' 
diagnostic scoring system for the differential diagnosis of tuberculous meningitis and 
bacterial meningitis. Jpn J Infect Dis 2014; 67(6): 428-31. 
23. Saavedra JS, Urrego S, Toro ME, et al. Validation of Thwaites Index for 
diagnosing tuberculous meningitis in a Colombian population. J Neurol Sci 2016; 370: 
112-8. 
24. Checkley AM, Njalale Y, Scarborough M, Zjilstra EE. Sensitivity and specificity 
of an index for the diagnosis of TB meningitis in patients in an urban teaching hospital in 
Malawi. Trop Med Int Health 2008; 13(8): 1042-6. 
25. Riley RD, Ensor J, Snell KI, et al. External validation of clinical prediction 
models using big datasets from e-health records or IPD meta-analysis: opportunities and 
challenges. BMJ 2016; 353: i3140. 
26. World Health Organization. Global tuberculosis report 2019. 2019. 
27. Thao LTP, Heemskerk AD, Geskus RB, et al. Prognostic Models for 9-Month 
Mortality in Tuberculous Meningitis. Clin Infect Dis 2018; 66(4): 523-32. 
28. Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood 
tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2014; 
14(10): 947-57. 
29. Wen L, Li M, Xu T, Yu X, Wang L, Li K. Clinical features, outcomes and 
prognostic factors of tuberculous meningitis in adults worldwide: systematic review and 
meta-analysis. J Neurol 2019; 266(12): 3009-21. 
30. Wang MG, Luo L, Zhang Y, Liu X, Liu L, He JQ. Treatment outcomes of 
tuberculous meningitis in adults: a systematic review and meta-analysis. BMC Pulm Med 
2019; 19(1): 200. 
31. Heemskerk AD, Bang ND, Mai NT, et al. Intensified Antituberculosis Therapy in 
Adults with Tuberculous Meningitis. N Engl J Med 2016; 374(2): 124-34. 
32. Woldeamanuel YW, Girma B. A 43-year systematic review and meta-analysis: 
case-fatality and risk of death among adults with tuberculous meningitis in Africa. J 
Neurol 2014; 261(5): 851-65. 
33. van Laarhoven A, Dian S, Ruesen C, et al. Clinical Parameters, Routine 
Inflammatory Markers, and LTA4H Genotype as Predictors of Mortality Among 608 
Patients With Tuberculous Meningitis in Indonesia. J Infect Dis 2017; 215(7): 1029-39. 
 
68 
34. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of 
tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351(17): 1741-51. 
35. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic 
review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1. 
36. Freeman MF, Tukey JW. Transformations Related to the Angular and the Square 
Root. Ann Math Stat 1950; 21(2): 305-. 
37. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-
analysis of binomial data. Arch Public Health 2014; 72(1): 39. 
38. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 
1986; 7(3): 177-88. 
39. Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC. metan: 
fixed- and random-effects meta-analysis. Stata J 2008; 8(1): 3-28. 
40. Downs SH, Black N. The feasibility of creating a checklist for the assessment of 
the methodological quality both of randomised and non-randomised studies of health care 
interventions. J Epidemiol Community Health 1998; 52(6): 377-84. 
41. Luma HN, Tchaleu BC, Ngahane BH, et al. Tuberculous meningitis: presentation, 
diagnosis and outcome in hiv-infected patients at the douala general hospital, cameroon: 
a cross sectional study. Aids Res Ther 2013; 10(1): 16. 
42. Marais S, Pepper DJ, Schutz C, Wilkinson RJ, Meintjes G. Presentation and 
outcome of tuberculous meningitis in a high HIV prevalence setting. PLoS One 2011; 
6(5): e20077. 
43. Thinyane KH, Motsemme KM, Cooper VJ. Clinical Presentation, Aetiology, and 
Outcomes of Meningitis in a Setting of High HIV and TB Prevalence. J Trop Med 2015; 
2015: 423161. 
44. Cresswell FV, Bangdiwala AS, Bahr NC, et al. Can improved diagnostics reduce 
mortality from Tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. 
Wellcome Open Res 2018; 3: 64. 
45. Raberahona M, Rakotoarivelo RA, Razafinambinintsoa T, Andrianasolo RL, 
Randria MJ. Clinical Features and Outcome in Adult Cases of Tuberculous Meningitis in 
Tertiary Care Hospital in Antananarivo, Madagascar. Biomed Res Int 2017; 2017: 
9316589. 
46. Gonzalez-Duarte A, Ponce de Leon A, Osornio JS. Importance of differentiating 
Mycobaterium bovis in tuberculous meningitis. Neurol Int 2011; 3(3): e9. 
47. Alarcon F, Moreira J, Rivera J, Salinas R, Duenas G, Van den Ende J. 
Tuberculous meningitis: do modern diagnostic tools offer better prognosis prediction? 
Indian J Tuberc 2013; 60(1): 5-14. 
48. Torok ME, Chau TT, Mai PP, et al. Clinical and microbiological features of HIV-
associated tuberculous meningitis in Vietnamese adults. PLoS One 2008; 3(3): e1772. 
49. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy 
in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect 
Dis 2011; 52(11): 1374-83. 
50. Thwaites GE, Chau TT, Caws M, et al. Isoniazid resistance, mycobacterial 
genotype and outcome in Vietnamese adults with tuberculous meningitis. Int J Tuberc 
Lung Dis 2002; 6(10): 865-71. 
51. Thwaites GE, Caws M, Chau TT, et al. Comparison of conventional bacteriology 
with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of 
 
69 
tuberculous meningitis before and after inception of antituberculosis chemotherapy. J 
Clin Microbiol 2004; 42(3): 996-1002. 
52. Singh AK, Malhotra HS, Garg RK, et al. Paradoxical reaction in tuberculous 
meningitis: presentation, predictors and impact on prognosis. BMC Infect Dis 2016; 16: 
306. 
53. Tai MS, Sharma VK. Role of Transcranial Doppler in the Evaluation of 
Vasculopathy in Tuberculous Meningitis. PLoS One 2016; 11(10): e0164266. 
54. Chen CH, Chang YJ, Sy HN, Chen WL, Yen HC. Risk assessment of the outcome 
for cerebral infarction in tuberculous meningitis. Rev Neurol (Paris) 2014; 170(8-9): 512-
9. 
55. Kalita J, Misra UK, Prasad S, Bhoi SK. Safety and efficacy of levofloxacin versus 
rifampicin in tuberculous meningitis: an open-label randomized controlled trial. J 
Antimicrob Chemother 2014; 69(8): 2246-51. 
56. Sheu JJ, Hsu CY, Yuan RY, Yang CC. Clinical characteristics and treatment 
delay of cerebral infarction in tuberculous meningitis. Intern Med J 2012; 42(3): 294-300. 
57. Wasay M, Farooq S, Khowaja ZA, et al. Cerebral infarction and tuberculoma in 
central nervous system tuberculosis: frequency and prognostic implications. J Neurol 
Neurosurg Psychiatry 2014; 85(11): 1260-4. 
58. Chotmongkol V, Jitpimolmard S, Thavornpitak Y. Corticosteroid in tuberculous 
meningitis. J Med Assoc Thai 1996; 79(2): 83-90. 
59. Lu CH, Chang WN, Chang HW. The prognostic factors of adult tuberculous 
meningitis. Infection 2001; 29(6): 299-304. 
60. Wang JT, Hung CC, Sheng WH, Wang JY, Chang SC, Luh KT. Prognosis of 
tuberculous meningitis in adults in the era of modern antituberculous chemotherapy. J 
Microbiol Immunol Infect 2002; 35(4): 215-22. 
61. Chotmongkol V, Panthavasit J, Tiamkao S, Jitpimolmard S. Tuberculous 
meningitis in adults: a four-year review during 1997-2000. Southeast Asian J Trop Med 
Public Health 2003; 34(4): 869-71. 
62. Thwaites GE, Simmons CP, Than Ha Quyen N, et al. Pathophysiology and 
prognosis in vietnamese adults with tuberculous meningitis. J Infect Dis 2003; 188(8): 
1105-15. 
63. Malhotra HS, Garg RK, Singh MK, Agarwal A, Verma R. Corticosteroids 
(dexamethasone versus intravenous methylprednisolone) in patients with tuberculous 
meningitis. Ann Trop Med Parasitol 2009; 103(7): 625-34. 
64. Hsu PC, Yang CC, Ye JJ, Huang PY, Chiang PC, Lee MH. Prognostic factors of 
tuberculous meningitis in adults: a 6-year retrospective study at a tertiary hospital in 
northern Taiwan. J Microbiol Immunol Infect 2010; 43(2): 111-8. 
65. Sharma SR, Lynrah KG, Sharma N, Lyngdoh M. Directly observed treatment, 
short course in tuberculous meningitis: Indian perspective. Ann Indian Acad Neurol 2013; 
16(1): 82-4. 
66. Sun F, Ruan Q, Wang J, et al. Linezolid manifests a rapid and dramatic 
therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob 
Agents Chemother 2014; 58(10): 6297-301. 
67. Kalita J, Prasad S, Misra UK. Predictors of paradoxical tuberculoma in 
tuberculous meningitis. Int J Tuberc Lung Dis 2014; 18(4): 486-91. 
 
70 
68. Imam YZ, Ahmedullah HS, Akhtar N, et al. Adult tuberculous meningitis in 
Qatar: a descriptive retrospective study from its referral center. Eur Neurol 2015; 73(1-
2): 90-7. 
69. Zhang J, Hu X, Hu X, et al. Clinical features, Outcomes and Molecular Profiles of 
Drug Resistance in Tuberculous Meningitis in non-HIV Patients. Sci Rep 2016; 6: 19072. 
70. Kalita J, Bhoi SK, Betai S, Misra UK. Safety and efficacy of additional 
levofloxacin in tuberculous meningitis: A randomized controlled pilot study. 
Tuberculosis (Edinb) 2016; 98: 1-6. 
71. Li K, Tang H, Yang Y, et al. Clinical features, long-term clinical outcomes, and 
prognostic factors of tuberculous meningitis in West China: a multivariate analysis of 154 
adults. Expert Rev Anti Infect Ther 2017; 15(6): 629-35. 
72. Mai NT, Dobbs N, Phu NH, et al. A randomised double blind placebo controlled 
phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. 
Elife 2018; 7. 
73. Cagatay AA, Ozsut H, Gulec L, et al. Tuberculous meningitis in adults--
experience from Turkey. Int J Clin Pract 2004; 58(5): 469-73. 
74. Doganay M, Calangu S, Turgut H, Bakir M, Aygen B. Treatment of tuberculous 
meningitis in Turkey. Scand J Infect Dis 1995; 27(2): 135-8. 
75. Sutlas PN, Unal A, Forta H, Senol S, Kirbas D. Tuberculous meningitis in adults: 
review of 61 cases. Infection 2003; 31(6): 387-91. 
76. Sengoz G, Yasar KK, Yildirim F. Evaluation of 121 adult cases of tuberculous 
meningitis. Neurosciences (Riyadh) 2008; 13(4): 402-7. 
77. Miftode EG, Dorneanu OS, Leca DA, et al. Tuberculous Meningitis in Children 
and Adults: A 10-Year Retrospective Comparative Analysis. PLoS One 2015; 10(7): 
e0133477. 
78. Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous 
meningitis. Cochrane Database Syst Rev 2016; 4: CD002244. 
79. Thuong NTT, Heemskerk D, Tram TTB, et al. Leukotriene A4 Hydrolase 
Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From 
Tuberculous Meningitis. J Infect Dis 2017; 215(7): 1020-8. 
80. Marais BJ, Heemskerk AD, Marais SS, et al. Standardized Methods for Enhanced 
Quality and Comparability of Tuberculous Meningitis Studies. Clin Infect Dis 2017; 
64(4): 501-9. 
81. Wilkinson RJ, Rohlwink U, Misra U.K., van Crevel R, Mai N.T.T., Dooley K.E. 
et al. . Tuberculous Meningitis. Nature Reviews: Neurology 2017. 
82. Tu JV. Advantages and disadvantages of using artificial neural networks versus 
logistic regression for predicting medical outcomes. Journal of Clinical Epidemiology 
1996; 49(11): 1225-31. 
83. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in 
developing models, evaluating assumptions and adequacy, and measuring and reducing 
errors. Statistics in Medicine 1996; 15(4): 361-87. 
84. Derksen S, Keselman HJ. Backward, Forward and Stepwise Automated Subset-
Selection Algorithms - Frequency of Obtaining Authentic and Noise Variables. Brit J 
Math Stat Psy 1992; 45: 265-82. 
85. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: 
rationale, conduct, and reporting. BMJ 2010; 340. 
 
71 
86. Ahmed I, Debray TP, Moons KG, Riley RD. Developing and validating risk 
prediction models in an individual participant data meta-analysis. BMC Med Res 
Methodol 2014; 14: 3. 
87. Debray TP, Moons KG, Ahmed I, Koffijberg H, Riley RD. A framework for 
developing, implementing, and evaluating clinical prediction models in an individual 
participant data meta-analysis. Stat Med 2013; 32(18): 3158-80. 
88. Jolani S, Debray TP, Koffijberg H, van Buuren S, Moons KG. Imputation of 
systematically missing predictors in an individual participant data meta-analysis: a 
generalized approach using MICE. Stat Med 2015; 34(11): 1841-63. 
89. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a 
multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD). Ann 
Intern Med 2015; 162(10): 735-6. 
90. Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for Systematic 
Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. 
JAMA 2015; 313(16): 1657-65. 
91. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the 
quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155(8): 529-36. 
92. Madley-Dowd P, Hughes R, Tilling K, Heron J. The proportion of missing data 
should not be used to guide decisions on multiple imputation. J Clin Epidemiol 2019; 
110: 63-73. 
93. Steyerberg EW, SpringerLink (Online service). Clinical prediction models : a 
practical approach to development, validation, and updating. New York: Springer; 2009. 
94. Brier GW. Verification of Forecasts Expressed in terms of probability. 1950. 
95. Anselmo LMP, Feliciano C, Mauad F, et al. A predictive score followed by 
nucleic acid amplification for adult tuberculous meningitis diagnosis in Southern Brazil. J 
Neurol Sci 2017; 379: 253-8. 
96. Gualberto FAS, Goncalves MG, Fukasawa LO, et al. Performance of nested RT-
PCR on CSF for tuberculous meningitis diagnosis in HIV-infected patients. Int J Tuberc 
Lung Dis 2017; 21(10): 1139-44. 
97. Azevedo RG, Dinallo FS, de Laurentis LS, Boulware DR, Vidal JE. Xpert 
MTB/RIF((R)) assay for the diagnosis of HIV-related tuberculous meningitis in Sao 
Paulo, Brazil. Int J Tuberc Lung Dis 2018; 22(6): 706-7. 
98. de Almeida SM, Borges CM, Santana LB, et al. Validation of Mycobacterium 
tuberculosis real-time polymerase chain reaction for diagnosis of tuberculous meningitis 
using cerebrospinal fluid samples: a pilot study. Clin Chem Lab Med 2019; 57(4): 556-
64. 
99. Nhu NT, Heemskerk D, Thu do DA, et al. Evaluation of GeneXpert MTB/RIF for 
diagnosis of tuberculous meningitis. J Clin Microbiol 2014; 52(1): 226-33. 
100. Heemskerk AD, Donovan J, Thu DDA, et al. Improving the microbiological 
diagnosis of tuberculous meningitis: A prospective, international, multicentre comparison 
of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of 
cerebrospinal fluid. J Infect 2018; 77(6): 509-15. 
101. Donovan J, Thu DDA, Phu NH, et al. Xpert MTB/RIF Ultra versus Xpert 
MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, 
diagnostic accuracy study. Lancet Infect Dis 2020; 20(3): 299-307. 
 
72 
102. Botha H, Ackerman C, Candy S, Carr JA, Griffith-Richards S, Bateman KJ. 
Reliability and diagnostic performance of CT imaging criteria in the diagnosis of 
tuberculous meningitis. PLoS One 2012; 7(6): e38982. 
103. Boulware DR, Meya DB. Antiretroviral therapy after cryptococcal meningitis. 
New England Journal of Medicine 2014; 371(12): 1166-7. 
104. Rhein J, Huppler Hullsiek K, Tugume L, et al. Adjunctive sertraline for HIV-
associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 
3 trial. Lancet Infect Dis 2019; 19(8): 843-51. 
105. Mitchell HK, Mokomane M, Leeme T, et al. Causes of Pediatric Meningitis in 
Botswana: Results From a 16-Year National Meningitis Audit. Pediatr Infect Dis J 2019; 
38(9): 906-11. 
106. Metcalf T, Soria J, Montano SM, et al. Evaluation of the GeneXpert MTB/RIF in 
patients with presumptive tuberculous meningitis. PLoS One 2018; 13(6): e0198695. 
107. Jipa R, Olaru ID, Manea E, Merisor S, Hristea A. Rapid Clinical Score for the 
Diagnosis of Tuberculous Meningitis: A Retrospective Cohort Study. Ann Indian Acad 
Neurol 2017; 20(4): 363-6. 
108. Christodoulou E, Ma J, Collins GS, Steyerberg EW, Verbakel JY, Van Calster B. 
A systematic review shows no performance benefit of machine learning over logistic 
regression for clinical prediction models. J Clin Epidemiol 2019; 110: 12-22. 
109. Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and 
external validation of predictive models: a simulation study of bias and precision in small 
samples. J Clin Epidemiol 2003; 56(5): 441-7. 
110. Kim JH. Estimating classification error rate: Repeated cross-validation, repeated 
hold-out and bootstrap. Computational Statistics & Data Analysis 2009; 53(11): 3735-45. 
111. Torok ME, Nghia HD, Chau TT, et al. Validation of a diagnostic algorithm for 
adult tuberculous meningitis. Am J Trop Med Hyg 2007; 77(3): 555-9. 
112. Solomons RS, Visser DH, Marais BJ, Schoeman JF, van Furth AM. Diagnostic 
accuracy of a uniform research case definition for TBM in children: a prospective study. 
Int J Tuberc Lung Dis 2016; 20(7): 903-8. 
113. Steyerberg EW, Vedder MM, Leening MJ, et al. Graphical assessment of 
incremental value of novel markers in prediction models: From statistical to decision 







Appendix A: Manuscript 1 Search Strategy  
# Database Search term Results 
1 Medline "TUBERCULOSIS, MENINGEAL"/ 6850 
2 Medline ((TB OR tubercul*) ADJ2 mening*).ti,ab 6694 
3 Medline ((TB OR tubercul*) ADJ2 (brain OR cerebral OR 
neurological)).ti,ab 
929 
4 Medline (1 OR 2 OR 3) 9169 
5 Medline exp MORTALITY/ 343596 
6 Medline exp "TREATMENT OUTCOME"/ 876952 
7 Medline exp "OUTCOME AND PROCESS ASSESSMENT 
(HEALTH CARE)"/ 
968126 
8 Medline exp "SURVIVAL ANALYSIS"/ 257144 
9 Medline "TUBERCULOSIS, MENINGEAL"/mo 192 
10 Medline "TUBERCULOSIS, MENINGEAL"/co 1175 
11 Medline (sequalae OR sequelae OR complication* OR outcome* OR 
death* OR mortality OR survival).ti,ab 
3381437 
12 Medline (5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11) 3965816 
13 Medline (4 AND 12) 2762 
14 Medline exp ADULT/ 6572439 
15 Medline (adult* OR age OR aged).ti,ab 3017488 
16 Medline (14 OR 15) 7975296 
17 Medline (13 AND 16) 1593 
18 EMBASE "TUBERCULOUS MENINGITIS"/ 6409 
19 EMBASE ((TB OR tubercul*) ADJ2 mening*).ti,ab 5995 
20 EMBASE ((TB OR tubercul*) ADJ2 (brain OR cerebral OR 
neurological)).ti,ab 
831 
21 EMBASE (18 OR 19 OR 20) 8847 
22 EMBASE exp *MORTALITY/ 129762 
23 EMBASE exp *"TREATMENT OUTCOME"/ 69616 
24 EMBASE exp *SURVIVAL/ 89772 
25 EMBASE *FATALITY/ 4759 
26 EMBASE exp *COMPLICATION/ 237190 
27 EMBASE *"ADVERSE OUTCOME"/ 4524 
28 EMBASE (sequalae OR sequelae OR complication* OR outcome* OR 
death* OR mortality OR survival).ti,ab 
4751087 
29 EMBASE (22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28) 4928804 
30 EMBASE (21 AND 29) 2534 
31 EMBASE exp *ADULT/ 97301 
32 EMBASE (adult* OR age OR aged).ti,ab 4369238 
33 EMBASE (31 OR 32) 4393218 










Appendix C: Manuscript 2 Search Strategy 
 
#1 Search tuberculosis meningitis Field: Title/Abstract 
#2 Search “tuberculosis, meningeal”[MeSH ] 
#3 Search cerebral tuberculosis Field: Title/Abstract 
#4 Search “brain tuberculosis” Field: Title/Abstract 
#5 Search TBM Field: Title/Abstract 
#6 Search ((((tuberculosis meningitis) OR “tuberculosis, meningeal”[MeSH Terms]) 
OR “cerebral tuberculosis“) OR “brain tuberculosis”) OR TBM 
#7 Search “Diagnosis”[Majr] 
#8 Search diagnosis or diagnostic Field: Title/Abstract 
#9 Search “clinical scores” or “clinical scoring” Field: Title/Abstract 
#10 Search “Research Design”[Mesh] 
#11 Search predictor* or predictive Filters: Field: Title/Abstract 
#12 Search “clinical predict*” Field: Title/Abstract 
#13 Search “clinical feature*” Field: Title/Abstract 
#14 Search (((#13 OR ((#12) OR ((#11) OR ((#10) OR ((#9) OR #8 OR #7 Filters: 
Humans 








Appendix E: Logistic Regression Coefficients with Average Intercept   
Covariate Odds Ratio (95% CI) p-value 
Intercept 0.53 (0.38-0.75) <0.001 
CSF WBC count, 100/mm3 0.92 (0.91-0.94) <0.001 
Neutrophilic Dominance 4.55 (3.37-6.14) <0.001 
Lymphocytic Dominance 4.74 (3.74-6.01) <0.001 
CSF Glucose, 10 mg/dL 0.67 (0.64-0.71) <0.001 
Blood Glucose, 10 mg/dL 1.06 (1.04-1.09) <0.001 
CSF CrAg Positive 0.03 (0.02-0.05) <0.001 
Fever 1.06 (1.34-1.92) <0.001 
HIV-positive 1.14 (0.94-1.37) 0.176 




Appendix F: Variable Importance in Random Forest Model 
Covariate Variable Importance* 
CSF Glucose, mg/dL 367.27 
CSF WBC count, cells/mm3 310.12 
CSF Protein, mg/dL 230.48 
Blood Glucose, 10 mg/dL 153.98 
CSF CrAg Positive 99.20 
Brazil 35.25 




CSF Neutrophilic Dominance 22.46 
Morocco 18.39 
Indonesia 17.33 





South Africa 5.48 
*Mean Decrease in Gini 
 
